DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           1 
CONFIDENTIAL  
 A Phase 1, Dosage -Escalation Study of the Safety and 
Immunogenicity of a Novel Rabies Vaccine ChAd155 -RG vs. the 
Comparator RABAVERT Vaccine in Healthy Adult Subjects  
 
DMID Protocol Number: 17 -0089  
 
Sponsor: National Institute of Allergy and Infectious Dis eases (NIAID)  
DMID Funding Mechanism: Vaccine and Treatment Evaluation Unit (VTEU)  
Pharmaceutical Support: reiThera/GlaxoSmithKline Vaccines  
 
Principal Investigator: Varun K. Phadke , MD  
DMID Medical Monitor: Tatiana Beresnev, MD, MSHS  
 
 
Version Number: 7.0 
 
19 January  2023 
  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           2 
CONFIDENTIAL  
 STATEMENT OF COMPLIANCE  
This trial will be carried out in accordance with Good Clinical Practice (GCP) and as required 
by: 
United States (US) Code of Federal Regulations (CFR) 45 CFR Part 46 (Protection of Human 
Subjects)  
Food and Drug Administration (FDA) Regulations, as applicable: 21 CFR Part 50 (Protection of 
Human Subjects), 21 CFR Part 54 (Financial Disclosure by Clinical Investigators), 21 CFR Part 
56 (Institutional Review Boards), 21 CFR Part 11  (Electronic Records and Elect ronic 
Signatures) , 21 CFR Part 312 (Investigational New Drug Application), and 21 CFR 812 
(Investigational Device Exemptions)  
International Conference on Harmonisation (ICH) E6 GCP; 62 Federal Register 25691 (1997); 
and future revisions  
Belmont Report: Eth ical Principles and Guidelines for the Protection of Human Subjects of 
Research, Report of the National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research  
National Institutes of Health (NIH) Office of Extramural Research,  Research Involving Human 
Subjects, as applicable  
National Institute of Allergy and Infectious Diseases (NIAID) Clinical Terms of Award, as 
applicable  
Applicable Federal, State, and Local Regulations and Guidance  
  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           3 
CONFIDENTIAL  
 SIGNATURE PAGE  
The signature below provid es the necessary assurance that this trial will be conducted according 
to all stipulations of this protocol, including all statements regarding confidentiality, and 
according to local legal and regulatory requirements and applicable US federal regulations and 
ICH E6 GCP guidelines.  
I agree to conduct this trial in compliance with GCP and applicable regulatory requirements.  
I agree to conduct this trial in accordance with the current protocol and will not make changes to 
this protocol without obtaining the s ponsor’s approval and IRB/IEC approval, except when 
necessary to protect the safety, rights, or welfare of subjects.  
Site Principal Investigator  Signature : 
 
Signed:   Date:   
 Name  
Title   
  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           4 
CONFIDENTIAL  
 TABLE OF CONTENTS  
Statement of Compliance  ................................ ................................ ................................ ................. 2 
Signature Page  ................................ ................................ ................................ ................................ .3 
Table of Contents  ................................ ................................ ................................ ............................. 4 
List of Tables  ................................ ................................ ................................ ................................ ...8 
List of Figures  ................................ ................................ ................................ ................................ ..9 
List of Abbreviations  ................................ ................................ ................................ ..................... 10 
Protocol Summary  ................................ ................................ ................................ ......................... 14 
1. Key Roles  ................................ ................................ ................................ ........................... 21 
2. Background Inform ation and Scientific Rationale  ................................ ............................ 23 
2.1. Background Information  ................................ ................................ ................................ ....23 
2.2  Rationale  ................................ ................................ ................................ ............................ 26 
2.3   Potential Risks and Benefits  ................................ ................................ ............................ 26 
2.3.1.  Potential Risks  ................................ ................................ ................................ ................... 26 
2.3.2  Known Potential Benefits  ................................ ................................ ................................ ..29 
3. Objectives and Outcome Measures  ................................ ................................ .................... 30 
3.1. Study Objectives  ................................ ................................ ................................ ................ 30 
3.1.1.  Primary  ................................ ................................ ................................ ............................... 30 
3.1.2.  Secondary  ................................ ................................ ................................ ........................... 30 
3.1.3.  Exploratory (if applicable)  ................................ ................................ ................................ .30 
3.2. Study Outcome Measures  ................................ ................................ ................................ ..30 
3.2.1.  Primary  ................................ ................................ ................................ ............................... 30 
3.2.2.  Secondary  ................................ ................................ ................................ ........................... 31 
3.2.3.  Explorato ry ................................ ................................ ................................ ........................ 31 
4. Study Design  ................................ ................................ ................................ ...................... 32 
4.1. Sub-studies (if applicable)  ................................ ................................ ................................ .33 
5. Study Enrollment and Withdrawal ................................ ................................ ..................... 34 
5.1. Subject Inclusion Criteria  ................................ ................................ ................................ ..34 
5.2. Subject Exclusion Criteria  ................................ ................................ ................................ .36 
5.3. Treatment Assignment Procedures  ................................ ................................ .................... 39 
5.3.1.  Randomization Procedures  ................................ ................................ ................................ 39 
5.3.2.  Masking Procedures  ................................ ................................ ................................ ........... 39 
5.3.3.  Reasons for Withdrawal and Discontinuation of Study Product Administration  .............. 40 
5.3.4.  Handling of Withdrawals and Discontinuation of Administration  ................................ ....41 
5.3.5.  Subje ct Replacement  ................................ ................................ ................................ .......... 41 
5.3.6.  Termination of Study  ................................ ................................ ................................ ......... 42 
6. Study Intervention/Investigational Product  ................................ ................................ .......43 
6.1. Study Product Description  ................................ ................................ ................................ .43 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           5 
CONFIDENTIAL  
 6.1.1.  Acquisition  ................................ ................................ ................................ ......................... 43 
6.1.2  Formulation, Packaging, and Labeling  ................................ ................................ .............. 43 
6.1.3  Product Storage and Stability ................................ ................................ ............................. 44 
6.2. Dosage, Preparation and Administration of Study Intervention/Investigational Product  ..46 
6.3. Accountability Procedures for the Study Investigational Product(s)  ................................ .47 
6.4. Concomitant Medications/Treatments  ................................ ................................ ............... 48 
7. Study Schedule ................................ ................................ ................................ ................... 49 
7.1. Recruitment  ................................ ................................ ................................ ........................ 49 
7.2. Screening ................................ ................................ ................................ ............................ 49 
7.2.1.  Visit 00A, Day -28 to -1, 1st Screen, Clinic Visit  ................................ ............................. 49 
7.2.2.  Visit 00B, Day -7 to -1, 2nd Screen, Clinic Visit – (only to repeat a screening 
assessment whose initial result is thought to be temporary)  ................................ .......................... 50 
7.3. Enrollment/Baseline  ................................ ................................ ................................ ........... 51 
7.3.1.  Visit 01, Day 1, Enrollment and First Vaccination  ................................ ............................ 51 
7.4. Follow -up ................................ ................................ ................................ ........................... 52 
7.4.1.  Visit 02, D ay 2 ................................ ................................ ................................ ................... 52 
7.4.2.  Visit 03, Day 8 (window: +2 days), Second Vaccination  ................................ .................. 53 
7.4.3.  Visit 04, Day 15 (window: +2 days), Third Vaccination  ................................ ................... 54 
7.4.4.  Visit 05, Day 16  ................................ ................................ ................................ ................. 55 
7.4.5.  Visit 06, Day 22 (window: +2 days), Fourth Vaccination  ................................ ................. 55 
7.4.6.  Visit 07, Day 29 (window: +1 day)  ................................ ................................ ................... 56 
7.4.7.  Phone Call, Visit 08, Day 50 (window +7 days)  ................................ ............................... 57 
7.4.8.  Visit 09, Day 91 (window ±7 days)  ................................ ................................ ................... 57 
7.4.9.  Visit 10, Day 181 (window ±14 days)  ................................ ................................ ............... 58 
7.5. Final Study Visit  ................................ ................................ ................................ ................ 58 
7.5.1.  Visit 11, Day 381 (window ±14 days)  ................................ ................................ ............... 58 
7.6. Early Termination Visit  ................................ ................................ ................................ .....59 
7.7. Unscheduled Visit  ................................ ................................ ................................ .............. 59 
8. Study Procedures/Evaluations  ................................ ................................ ........................... 61 
8.1. Clinical Evaluations  ................................ ................................ ................................ ........... 61 
8.2. Laboratory Evaluations  ................................ ................................ ................................ ......62 
8.2.1.  Clinical Laboratory Evaluations  ................................ ................................ ........................ 62 
8.2.2.  Special Assays  ................................ ................................ ................................ ................... 62 
8.2.3.  Specimen Preparation, Handling, and Shipping  ................................ ................................ 63 
9. Assessment of Safety  ................................ ................................ ................................ ......... 65 
9.1. Specification of Safety Parameters  ................................ ................................ .................... 65 
9.2. Methods and Timing for Assessing, Recording, and Analyzing Safety Parameters  ......... 65 
9.2.1.  Adverse Events  ................................ ................................ ................................ .................. 65 
9.2.2.  Reactogenicity ................................ ................................ ................................ .................... 67 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           6 
CONFIDENTIAL  
 9.2.3.  Serious Adverse Events  ................................ ................................ ................................ .....67 
9.2.4.  Procedures to be Foll owed in the Event of Abnormal Laboratory Test Values or 
Abnormal Clinical Findings  ................................ ................................ ................................ ........... 68 
9.3. Reporting Procedures  ................................ ................................ ................................ ......... 68 
9.3.1.  Serious Adverse Events  ................................ ................................ ................................ .....68 
9.3.2.  Regulatory Reporting for Studies Conducted Under DMID -Sponsored IND  ................... 69 
9.3.3.  Reporting of Pregnancy  ................................ ................................ ................................ .....69 
9.4. Type and Duration of Follow -up of Subjects after Adve rse Events  ................................ ..69 
9.5. Halting Rules  ................................ ................................ ................................ ..................... 70 
9.6. Safety Oversight ................................ ................................ ................................ ................. 73 
9.6.1.  Safety Review Committee (SRC)  ................................ ................................ ...................... 73 
9.6.2.  Safety Monitoring Committee (SMC)  ................................ ................................ ............... 73 
9.6.3. Independent Safety Monitor (ISM)  ................................ ................................ .................... 74 
10. Clinical Monitoring  ................................ ................................ ................................ ............ 76 
10.1.  Site Monitoring Plan  ................................ ................................ ................................ .......... 76 
11. Statistical Considerations  ................................ ................................ ................................ ...77 
11.1. Study Hypotheses ................................ ................................ ................................ ............... 77 
11.2.  Sample Size Considerations  ................................ ................................ ............................... 77 
11.2.1 Adverse Events  ................................ ................................ ................................ ................... 77 
11.2.2 Immunogenicity  ................................ ................................ ................................ .................. 79 
11.3.  Planne d Interim Analyses  ................................ ................................ ................................ ..80 
11.3.1.  Interim Safety Review  ................................ ................................ ................................ .......80 
11.3.2.  Interim Immunogenicity Review  ................................ ................................ ....................... 81 
11.4.  Final Analysis Plan  ................................ ................................ ................................ ............ 81 
11.4.1 Analysis Populations  ................................ ................................ ................................ ........... 81 
11.4.2 Baseline Characteristics  ................................ ................................ ................................ ......82 
11.4.3 Safety Analysis Plan  ................................ ................................ ................................ ........... 82 
11.4.4 Immunology Analysis Plan  ................................ ................................ ................................ .83 
11.4.5 Missing Values and Outliers  ................................ ................................ ............................... 84 
12. Source Documents and Access to Source Data/Documents  ................................ .............. 85 
13. Quality Control and Quality Assurance  ................................ ................................ ............. 86 
14. Ethics/Protection of Human Subjects  ................................ ................................ ................ 87 
14.1.  Ethical Standard  ................................ ................................ ................................ ................. 87 
14.2.  Institutional Review Board  ................................ ................................ ................................ 87 
14.3.  Informed Consent Process  ................................ ................................ ................................ .87 
14.4.  Exclusion of Women, Minorities, and Children (Special Populati ons) ............................. 89 
14.5.  Subject Confidentiality  ................................ ................................ ................................ ......89 
14.6.  Study Discontinuation  ................................ ................................ ................................ ........ 90 
14.7.  Costs, Subject Compensation, and Research Related Injuries  ................................ ........... 90 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           7 
CONFIDENTIAL  
 14.8.  Future Use of Stored Specimens and Data  ................................ ................................ ........ 90 
15. Data Handling and Record Keeping  ................................ ................................ .................. 92 
15.1.  Data Management Responsibilities ................................ ................................ .................... 92 
15.2.  Data Capture Methods  ................................ ................................ ................................ .......92 
15.3.  Types of Data  ................................ ................................ ................................ ..................... 93 
15.4.  Timing/Reports  ................................ ................................ ................................ .................. 93 
15.5.  Study Records Retention ................................ ................................ ................................ ....93 
15.6.  Protocol Deviations  ................................ ................................ ................................ ............ 93 
16. Publication Policy  ................................ ................................ ................................ .............. 95 
17. Literature References  ................................ ................................ ................................ ......... 96 
18. Supplements/Appendices  ................................ ................................ ................................ .100 
Appendix  A. Schedule of Study Procedures And Evaluations  ................................ ................. 101 
Appendix B. Table of Blood Volume Collection (mL ) ................................ ............................... 107 
Appendix C.  Toxicity Table  ................................ ................................ ................................ .......109 
  
  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           8 
CONFIDENTIAL  
   
LIST OF TABLES  
Table  1: Treatment Arms  ................................ ................................ ................................ ............... 20 
Table 2:  Probability of Observing an Adverse Event for Various Event Rates and Sample 
Sizes  ................................ ................................ ................................ ............................ 78 
Table 3 : Minimum Detectable Event Rates for Various Levels of Power and Sample Size  ......... 79 
Table 4 : 95% Confidence Intervals for Seroconversion Rate for Various Rates and 
Sample Sizes  ................................ ................................ ................................ ............... 79 
   
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           9 
CONFIDENTIAL  
 LIST OF FIGURES  
Figure 1: Rabies VNA titer kinetics in NHP  ................................ ................................ ................. 25 
 
  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           10 
CONFIDENTIAL  
  
LIST OF ABBREVIATIONS  
Ad Adenovirus  
AE Adverse Event/Adverse Experience  
ALT  Alanine Transaminase  
aPTT  Activated Partial Thromboplastin Time  
ASC  Antibody Secreting Cell  
AST  Aspartate Transaminase  
BMI  Body Mass Index  
BUN  Blood Urea Nitrogen  
CFR  Code of Federal Regulations  
CFSE  Carboxyfluorescein Diacetate Succinimidyl Ester 
ChAd  Chimpanzee Adenovirus  
CMS  Clinical Materials Services  
COI Conflict of Interest  
COVID -19 Coronavirus Disease 2019  
CPM  Clinical Project Manager  
CROMS  Clinical Research Operations and Management Support  
CSR  Clinical Study Report  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases, NIAID, 
NIH, DHHS  
eCRF  Electronic Case Report Form  
ELISA  Enzyme -linked Immuno -sorbent Assay  
ELISPOT  Enzyme -linked Immunospot  
FDA  Food and Drug Administration  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           11 
CONFIDENTIAL  
 FWA  Federal Wide Assurance  
GCP  Good Clinical Practice  
GMT  Geometric Mean Titer  
HCV  Hepatitis C Virus  
HIPAA  Health Insurance Portability and Accountability Act  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
ICS Intracellular Cytokine Staining  
IDES  Internet Data Entry System  
IEC Independent or Institutional Ethics Committee  
IM Intramuscular  
IND Investigational New Drug Application  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
ITT Intention -to-Treat  
IU International Unit  
IV Intravenous  
MOP  Manual of Procedures  
N Number (typically refers to subjects)  
NDA  New Drug Application  
NHP  Non-Human Primate  
NIAID  National Institute of Allergy and Infectious Diseases, NIH, 
DHHS  
NIH National Institutes of Health  
OCRR  Office of Clinical Research Resources  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           12 
CONFIDENTIAL  
 OHRP  Office for Human Research Protections  
OHSR  Office for Human Subjects Research  
PEP Post-Exposure Prophylaxis  
PHI Protected Health Information  
PI Principal Investigator  
PrEP  Pre-Exposure Prophylaxis  
PT Prothrombin Time  
QA Quality Assurance  
QC Quality Control  
RFFIT  Rapid Fluorescence Focus Inhibition Test  
RG Rabies Protein G  
RIG Rabies Immunoglobulin  
RSV  Respiratory Syncytial Virus  
SAE  Serious Adverse Event/Serious Adverse Experience  
SAP Statistical Analysis Plan  
SARS -CoV -2 Severe Acute Respiratory Syndrome Coronavirus 2  
SDCC  Statistical and Data Coordinating Center  
SMC  Safety Monitoring Committee  
SOC  System Organ Class  
SOP Standard Operating Procedure  
ULN  Upper Limit of Normal  
US United States  
VNA  Virus neutralizing antibody  
VP Viral Particle  
VTEU  Vaccine and Treatment Evaluation Unit  
WBC  White Blood Cell  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           13 
CONFIDENTIAL  
 WHO  World Health Organization  
  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           14 
CONFIDENTIAL  
 PROTOCOL SUMMARY  
Title:  A Phase 1, Dosage -Escalation Study of the Safety and 
Immunogenicity of a Novel Rabies Vaccine ChAd155 -RG vs. 
the Comparator RABAVERT Vaccine in Healthy Adult Subjects  
Phase:  1 
Population:  This trial will enroll 50 rabies - and adenovirus vaccine -naive 
healthy male and non -pregnant female subjects aged 18 to  49 
years, and will be conducted in the US.  
Number of Sites:  1 (Emory University VTEU)  
Study Duration:  This trial is expected to take approximately 48 months to 
complete, from initiation through availability of a final report on 
the primary and secondary outcomes of safety and rabies virus 
neutralizing antibody (VNA) responses.  
Estimated Time to Complete 
Enrollment:   
Enrollment is expected to take up to 18 months from study 
initiation.  
Subject Participation 
Duration:  The duration of each subjec t’s participation is approximately 13 
months, from recruitment through the last study visit.  
Description of Agent or 
Intervention:  The investigational product is ChAd155 -RG Vaccine, 
administered in one or two doses, and the commercially 
available, active comparator is RABAVERT Vaccine, 
administered in three doses, by the intramuscular (IM) route. All 
subjects will receive one or more doses of an experimental or 
licensed vaccine . 
Objectives   
Primary  
• Assessment of the safety, tolerability, and reactogenicity 
of one dose of ChAd155 -RG at 5x1010vp per dose, or one 
or two doses of ChAd155 -RG at 1x1011vp per dose.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           15 
CONFIDENTIAL  
 • Comparison of the safety, tolerability, and reactogenicity 
of one or two doses of ChAd155 -RG, with three doses of 
RAB AVERT.   
Secondary  
• Assessment of serum rabies VNA levels by a standard, 
WHO -approved, RFFIT, as assessed by immune response 
kinetics (through approximately 12 months after first dose 
of vaccine), seroconversion rates, and peak GMT in each 
treatment arm.  
Exploratory (if applicable)  
• Quantification of circulating T -cell responses against RG 
by ex vivo IFN -gamma ELISpot.  
• Characterization of circulating CD4 and CD8 T -cell 
responses against RG at peak time point by 
multiparameter ICS.  
• Comparison of durabi lity of immune response to 
ChAd155 -RG and RABAVERT at approximately 3, 6, 
and 12 months after first dose of vaccine by each 
treatment arm tested.  
• Measurement of RG -specific memory B cells by ELISpot.  
• Measurement of an antibody response to the vaccine 
vector (ChAd155).  
Outcome Measures:  Primary  
• Frequency and severity of solicited injection site and 
systemic reactogenicity events from the time of each 
vaccination through Day 7 after each vaccination, in each 
treatment arm and overall.  
• Frequency and severity of SAEs considered study 
vaccine -related and reported at any time after the first 
vaccination through the end of the study, in each 
treatment arm and overall.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           16 
CONFIDENTIAL  
 • Frequency and severity of study vaccine -related lab AEs 
through Day 22 f rom the time of the first vaccination , in 
each treatment arm and overall.  
• Frequency and severity of unsolicited study vaccine -
related AEs from the time of the first vaccination through 
Day 28 after the last vaccination, in each treatment arm 
and overall . 
• Number of subjects with new onset of a chronic medical 
condition at any time after the first vaccination, in each 
treatment arm and overall.  
• Frequency and severity of any SAEs at any time after the 
first vaccination through the end of the study, in each 
treatment arm and overall.  
Secondary  
• Proportion of subjects seroconverting to rabies virus at 
each antibody time point (seroconversion is defined as 
VNA concentration  ≥0.5 IU/mL), in each treatment arm 
and overall.  
• GMT (as measured by rabies VNA using a standard, 
WHO -approved, RFFIT) at each antibody time point 
within each treatment arm.  
• Peak GMT (as measured by rabies VNA using a standard, 
WHO -approved, RFFIT; peak GMT is defined as highest 
GMT measured across all post -vaccination antibody time  
points) within each treatment arm.  
Exploratory  
• Frequencies of circulating T cell responses against RG by 
ex vivo IFN -ELISpot.  
• Characteristics of circulating CD4 and CD8 T cell 
responses against RG by multiparameter ICS.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           17 
CONFIDENTIAL  
 • Magnitude and durability of RG-specific memory B cells 
by ELISpot.  
• GMT to ChAd155 vector at one month after first 
vaccination  
Description of Study Design:   
This is a single -center, observer -blinded, Phase 1, dosage -
escalation trial to evaluate the safety, tolerability, reactogenicity, 
and immunogenicity of ChAd155 -RG compared with 
RABAVERT in rabies virus -naïve healthy male and non -
pregnant female adult subjects. There are 4 dose groups 
(Table  1). 
Subjects who have never received a licensed or investigational 
rabies virus vaccine, or an Adenovirus (Ad) -based 
investigational vaccine, and who have never been exposed to a 
rabid animal wil l be eligible for enrollment.  
Since this is a dosage -escalation study, sentinel subjects will be 
used at each dosage level. The first four subjects  will be  
randomized to Group A or D and will receive either a single dose 
of ChAd155 -RG at the lower dosage ( 5x1010vp, N=3) (followed 
by placebo on Days 8, 15, and 22) or RABAVERT  (N=1)  (on 
Days 1, 8, and 22, and placebo on Day 15) (see Table  1). These 
subjects will be monitored for safety, tolerability, and 
reactogenicity through day 7 after first study vaccination , and if 
no pre -defined halting rule is met (Section 9), then four 
additional sentinel subjects will be randomized to  Group B or D 
and will  receive eith er a single dose of ChAd155 -RG at the 
higher dosage (1x1011vp, N=3) (followed by placebo on Days 8, 
15, and 22) or RABAVERT  (N=1)  (on Days 1, 8, and 22, and 
placebo on Day 15)  (see Table  1). These subjects will be 
monitored for safety, tolerability, and reactogenicity through day 
7 after first study vaccination. The Safety Monitoring Committee 
(SMC ) will then review the available safety, reactogenicity, AE, 
and lab data of  all the sentinel subjects, and will decide if the 
remaining non-sentinel subjects should be enrolled.   
If the SMC recommends proceeding with the remainder of trial 
enrollment, eligible individuals will be enrolled and randomized 
to one of the four dose groups (Groups A-D). To maintain 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           18 
CONFIDENTIAL  
 blinding of study personnel conducting surveillance and 
assessment of AEs, subjects in these groups will receive 4 
sequential injections, 1 ml per injection, in alternating  arms, on 
the same schedule:  
• Subjects randomized to Group A will receive ChAd155 -
RG at the lower dosage (5x1010vp) on Day 1, then 
placebo injections on Day s 8, 15, and 22  
• Subjects randomized to Group B will receive ChAd155 -
RG at the higher dosage (1x1011vp) on Day 1, then 
placebo injections on Day s 8, 15, and 22  
• Subjects randomized to Group C will receive ChAd155 -
RG at the higher dosage (1x1011vp) on Day s 1 and 15, 
and placebo injections on Day s 8 and 22  
• Subjects randomized to Group D will receive 
RABAVERT at the standard dose (1  mL) on Day s 1, 8, 
and 22, and a placebo injection on Day 15  
Vaccine preparation and administration will be unblinded. The 
investigational vaccine doses will be prepared just prior to 
administration to ensure that the volume of each injection is 
identical between Groups A -D. Follow -up will be double -
blinded, and the SMC will review the available safety, 
reactogenicity, AE, and lab data collected from all subjects for 7 
days after the last vaccination and as needed.  
Subjects will be fo llowed using a memory aid, face -to-face 
scheduled clinic visits, and safety lab monitoring as outlined in 
Section 7 and Appendix  A. Following enrollment and 
vaccination, s afety lab blood samples will be c ollected on Days 
2, 8, 16, and 22. Blood samples for immunologic assays will be 
collected on Days 1, 2, 8, 15, 16, 22, 29, 9 1, 181, and 3 81. The 
duration of each subject’s participation will be approximately 13 
months, from recruitment to collection of dat a for safety and 
immunogenicity outcomes.  
This trial is expected to take approximately 30 months to 
complete, from initiation through availability of a final report on 
the primary outcomes of safety and the secondary outcomes of 
VNA levels to RG. Exploratory outcomes are discussed in an 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           19 
CONFIDENTIAL  
 addendum. A planned interim safety, reactogenicity, and 
immunogenicity analysis is detailed in Section  11.3. 
 
  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           20 
CONFIDENTIAL  
 Table  1: Treatment Arms  
 
Study 
Group  N Vaccine  Dosage of 
Vaccine  Number 
of 
Vaccine 
Doses  Schedule  of 
Vaccine and 
Placebo 
Injections  Route  Description  
of Study 
Group  
A 14 
including 3 
sentinels# ChAd155
-RG 5x1010vp* 1 Day 1  
vaccine; Days 
8, 15, and 22 
placebo  IM Lower 
dosage, 1 
dose 
B 14 
including 3 
sentinels  ChAd155
-RG 1x1011vp 1 Day 1  
vaccine; Days 
8, 15, and 22 
placebo  IM Higher 
dosage, 1 
dose 
C 10 ChAd155
-RG 1x1011vp 2 Days 1 and 15  
vaccine; Days 
8 and 22 
placebo  IM Higher 
dosage, 2 
doses  
D 12 
including 2 
sentinel s RABA -
VERT  1 mL  3 Days 1, 8, and 
22 vaccine; 
Day 15 
placebo  IM Active 
comparator 
(licensed 
vaccine)  
*Abbreviations: vp, viral particles; IM, intramuscular  
#Groups A , B and D each include  sentinel subjects as indicated.  Note: Two of the sentinels will 
receive a three -dose series  of RABAVERT . To maintain blinding , the other sentinels will receive 
placebo injections on Days 8, 15, and 22 as indicated in the table.   
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           21 
CONFIDENTIAL  
 1. KEY ROLES    
Individuals:  
Principal Investigator:  
 
                                      
 
 
  
Varun K. Phadke, MD  
Assistant  Professor of Medicine, Division of Infectious 
Diseases  
Emory University Vaccine and Treatment Evaluation Unit 
(VTEU)  
The Hope Clinic of the Emory Vaccine Center  
500 Irvin Court, Suite 200  
Decatur, GA 30030  
Phone: 404 -712-9046  
Fax: 404 -499-9728  
Email: vphadke@emory.edu  
 
DMID  Clinical Project 
Manager : 
 Gabriele Malone , RN, MSN  
Virology Branch  
DMID/NIAID, NIH  
 
DMID  Scientific 
Lead/Program Officer  
 Walla Dempsey , PhD  
Virology Branch  
DMID/NIAID, NIH, HHS  
 
DMID Medical Monitor : Tatiana Beresnev, MD, MSHS  
DMID/NIAID , NIH 
5601 Fishers Lane, Room 7E5 4 
Bethesda , MD 208 92-9826  
Office: 301-761-7062  
Email: beresnet@mail.nih.gov  
 
DMID  Medical Officer : 
 Francisco Levya , MD, PhD , ScM  
DMID/NIAID, NIH  
 
Institution:   
Emory University VTEU  
Hope Clinic  
500 Irvin Court, Suite 200  
Nadine Rouphael, MD  
Phone: 404-712-1435  
Fax: 404-499-9727 
E-mail: nroupha@emory.edu   
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           22 
CONFIDENTIAL  
 Safety and 
Pharmacovigilance 
Contractor:  
 DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support 
(CROMS)  
6500 Rock Spring Drive, Suite 650  
Bethesda, MD 20817  
SAE Hot Line: 1 -800-537-9979 (US)  
SAE Fax: 800 -275-7619 (US)  
SAE Email: PVG@dmidcroms.com  
 
Data Coordinating Center:  
  
The Emmes Corporation  
401 N. Washington Street, Suite 700  
Rockville, MD  20850  
Phone: 301 -251-1161  
Fax: 301 -576-3558  
Email: virology@emmes.com  
 
Study Agent Repository:  
 Fisher BioServices  
c/o DMID Clinical Materials Services (CMS)  
20439 Seneca Meadows Parkway  
Germantown, MD 20876  
Phone: 240 -477-1350  
Fax: 240 -477-1360  
Email: DMID.CMS@thermofisher.com  
 
Laboratories : Local Clinical Laboratory:  
Quest Diagnostics  
 
Research Laboratories:  
Emory Infectious Diseases Clinical Research Laboratory  
Kansas State University Laboratory  
  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           23 
CONFIDENTIAL  
 2. BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE  
2.1. Background Information  
 
Rabies is an acute, progressive viral encephalitis caused by neurotropic single -stranded RNA 
viruses (genus Lyssavirus, family Rhabdoviridae). This zoonotic infection is acquired after 
exposure to the saliva of infected domestic or wild mammals and is almo st invariably fatal. 
Rabies is estimated to cause more than 50,000 deaths annually, mostly in Asia and Africa, but 
the true disease burden is likely higher due to underreporting and lack of confirmatory testing in 
many endemic regions.1, 2 
Highly effective, inactivated viral vaccines against rabies have been available for use as pre -
exposure prophylaxis (PrEP) or post -exposure prophylaxis (PEP) for decades. In the US, two 
vaccine formulations are  currently available, a purified chick embryo cell vaccine (PCECV; 
RabAvert, GSK Vaccines), and a human diploid cell vaccine (HDCV; Imodex, Sanofi Pasteur).3, 
4 It is recommended that both vaccines be administered in a three -dose series (Days 0, 7, and 21 
or 28)3 for PrEP, and a four -dose series (Days 0, 3, 7, and 14; a fifth dose on Day 28 is 
recommended for immunocompromised indi viduals) for PEP, with or without rabies 
immunoglobulin (RIG) depending on the severity of the exposure.4 Virtually all recipients of a 
recommended vaccine series mount a seroprotective titer of rabies VNA, defined as a post -
vaccination VNA concentr atin ≥0.5 IU/mL, or complete virus neutralization at a 1:5 serum 
dilution, by a WHO -approved RFFIT.  
Despite the existence of effective vaccines, rabies remains endemic throughout the world. This is 
largely because RIG and/or rabies vaccines are not readily available, especially in countries with 
a high animal rabies burden, and because the recommended schedule of vaccine administration is 
cumbersome and cost -prohibitive. Even in the US, compliance with the recommended PEP 
vaccine series is suboptimal ; for example, in one prospective study of rabies PEP, over one-third 
of individuals failed to complete  the PEP vaccine series at 1 month.5 Thus, novel vaccines 
against rabies that are safe, tolerable, economical, and as immunogenic as current formulations, 
and that can be administered for PrEP  in one  dose, and for PEP in one or two doses, are urgently 
needed.  
Modified live viral -vectored rabies vaccines – given as a single dose – have been used 
successfully in animals for decades ; thus, a similar approach could be applied against human 
rabies. For example, RG -canarypox virus and RG -vaccinia virus vaccines are currently in use in 
the US for vaccination of domestic cats and wildlife, respectively.6 In humans, r eplication -
defective chimpanzee adenovirus (ChAd) vectors are being  increasingly recognized as attractive 
vaccine vector candidates.7 Given the lower probability of pre -existing immunity to the ChAd 
vector in humans, ChAd -vectored vaccines have the potential to elicit high -quality, durable 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           24 
CONFIDENTIAL  
 immune responses.8 In fact, safe and immunogenic ChAd -vectored human vaccines have already 
been described for Ebola,9-12 malaria,13 hepatitis C virus (HCV),14 and respiratory syncytial virus 
(RSV).15 
Ad vaccine carriers have also been shown to be effective for rabies, but only in animals. For 
example, i n Canada, an oral rabies vaccine (ORV) consisting of replication -competent 
recombinant human adenovirus type 5 (Ad5) expressing RG within an E3 deletion (referred to as 
AdRG1.3,16 or ONRAB®) is licensed for use as vaccine bait in animal rabies control efforts,17 
and has also been evaluated in multiple US field trials.18-20 More recently, Xiang et al. described 
a novel rabies vaccine consisting of replication -defective recombinant ChAd  vector serotype 
SAd-V24 (referred to as Ad68C) expressing RG using a non -human primate (NHP) model.21 
Notably, after only a single IM injection  in this model,  this vaccine elic ited sustained levels of 
seroprotective VNAs through 21 months post -vaccination, and provided 100% protection from 
lethal rabies virus challenge at 22 months post vaccination.21 
ReiThera has recently developed a novel rabies vaccine aimed at extending these findings into 
humans. The vaccine, ChAd155 -RG, consists of a replication -defective group C ChAd 155 
(ChAd155) expressing RG under the control of the CMV pro moter. Group C Ad vectors 
(including human Ad5 and ChAd3) have previously been shown to be safe, tolerable, and highly 
immunogenic in humans.9-12, 14, 15 A recombinant RSV -ChAd155 vaccine has also been tested 
successfully in a Phase 1 clinical trial.22 To increase the cross -protective breadth of ChAd155 -
RG, the RG sequence is a medoid, a natural viral strain with the highest average percent of 
amino acid identity among all RG sequences annotated in NCBI’s database. The selected RG 
protein (NCBI  strain AGN94271) shares an average 94% percent identity to the RG proteins of 
current vaccines.  
In preclinical studies in mice, ChAd155 -RG elicited seroprotective VNA concentrations  (≥0.5 IU/mL) 
over a wide dosage range and conferred protection against a lethal challenge with a rabies virus strain 
(unpublished data). Immunogenicity studies were subsequently conducted in NHP models with the aim of 
assessing up to 1 year the kinetics, breadth, and longevity of VNA titers induced by a single IM 
immunization w ith ChAd155 -RG compared with three doses (Days 0, 7, and 21) of a comparator cell 
culture -derived vaccine (CCV), RABIPUR (sold in the US as RABAVERT). In these experiments, three 
groups of five cynomolgus monkeys ( Macaca fascicularis ) received rabies vacci ne: Groups 1 and 2 
received a single dose of 5x1010vp ChAd155 -RG at Day 0, whereas Group 3 received three doses of 
RABIPUR at Days 0, 7, and 21. For both vaccines, half of the intended human dosage was used. Group 2 
monkeys subsequently received one dose o f RABIPUR 24 weeks after the first vaccination to analyze the 
capacity of VNA titers induced by the vectored vaccine to be boosted by a CCV vaccine.  Near the end of 
the study at week 48 after the first vaccination, all animals in Groups 1 and 2 received a final 5x1010vp 
booster dose of ChAd155 -RG as a recall vaccination.  
The results (Figure 1) showed that a single IM immunization with ChAd155 -RG elicited VNA titers 
above the protective threshold in all 10 animals in Groups 1 and 2 by just two  weeks after vaccination. 
Titers peaked between week 2 and 4 post-vaccination and were of comparable magnitude to those 
induced by three vaccinations with RABIPUR. VNA kinetics and levels remained similar between 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           25 
CONFIDENTIAL  
 ChAd155 -RG and RABIPUR vaccinated animals over 6 months of follow up. VNA concentra tions  were 
stable and above 0.5 IU/m L up to week 48 (~1  year) after a single ChAd155 -RG administration in Group 
1 animals.  
 
Figure 1: Rabies VNA titer kinetics in NHP  
 
Rabies vaccine immunogenicity study in NHPs. Groups of 5 cynomolgus monkeys were vaccinated as 
highlighted by arrows on the x-axis with half of the human dose of ChAd155 -RG vector (Groups 1 and 2) 
and RABIPUR, injected in the muscle. Rabies VNA titers were  measured with a Fluorescent Antibody 
0 2 4 8 1 2 1 6 2 0 2 4 2 6 2 8 3 2 3 6 4 0 4 4 4 8 5 0 5 20 .111 01 0 01 ,0 0 01 0 ,0 0 0ra b ie s  n A b  (IU /m l)3 .R A B IP U R2 .C h A d /R A B /C h A d1 .C h A d /C h A d
w e e k s
C h A d R A B IP U RC h A d
R A B IP U R0 .5
0 2 4 8 1 2 1 6 2 0 2 4 2 6 2 8 3 2 3 6 4 0 4 4 4 8 5 0 5 20 .111 01 0 01 ,0 0 0ra b ie s  n A b  (IU /m l)3 .R A B IP U R2 .C h A d /R A B /C h A d1 .C h A d /C h A d
0 .5
C h A d R A B IP U RC h A d
R A B IP U RA
B
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           26 
CONFIDENTIAL  
 Virus Neutralization (FAVN) assay (at IDEXX; Germany) and followed starting at 2 weeks post 
vaccination and then monthly. A: Data for individual animals, B: Group median +/ - IQR 
 
The RABIPUR boost in Group 2 animals at  week 24 was highly efficient in raising VNA titers 
even above the peak level achieved with the ChAd155 -RG prime, suggesting compatibility of the 
two rabies vaccines. The boost with ChAd155 -RG at week 48 was also highly effective: VNA 
titers increased well  above peak post prime in Group 1, similar to what was seen in Group 2 
upon RABIPUR boost , highlighting the possibility and potential efficacy of re -administering the 
candidate ChAd155 -RG vaccine.  
Together, these preclinical data demonstrate the potential for ChAd155 -RG to be a promising 
novel rabies vaccine candidate in humans, and thus warrant further evaluation in a Phase 1 
clinical trial.  
2.2  Rationale  
This trial will assess the safety, tolerability, and reactogenicity of ChAd155 -RG in comparison 
with RABAVERT. This trial will also determine whether the immunogenicity data generated in 
NHP studies can be replicated in a clinical setting, using a standard WHO -approved RFFIT to 
measure VNA responses, and evaluate the durability of the immune response to C hAd155 -RG in 
comparison with RABAVERT up to 1 year after vaccination.  
The ChAd155 -RG dosage and regimen selected for this trial are based on past experience with 
ChAd -vectored vaccines, non -clinical data from ChAd155 -RG immunizations in NHPs, as well 
as a desire to evaluate this novel vaccine as rabies PrEP ( one or two  doses) in comparison with 
commercially available RABAVERT as PrEP (recommended three doses).  
Finally, exploratory endpoint assays will be performed to broadly characterize the short - and 
long-term immune responses to ChAd155 -RG compared with RABAVERT.  
2.3   Potential Risks and Benefits  
2.3.1.  Potential Risks  
This is a Phase 1 dosage -escalation study of the investigational ChAd155 -RG Vaccine. The 
potential risks of this trial are those related to ChAd155 -RG, the comparator RABAVERT 
Vaccine, having blood drawn, IM injection, other risks, and breach of confidentiality.  
RABAVERT  
RABAVERT was licensed by the FDA for use as rabies PrEP or PEP in 1997. A comprehensive 
description of the risks  of AEs are described in the package insert.23 Notable potential risks 
related to RABAVERT administration are the potential occurrences of severe rare adverse 
neurological complications that hav e been previously reported in temporal association with 
vaccine administration. These include meningitis, encephalitis, neuroparalysis, transient 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           27 
CONFIDENTIAL  
 paralysis, Guillain -Barre syndrome, myelitis, retrobulbar neuritis, multiple sclerosis, vertigo, and 
visual di sturbances.23, 24 An analysis of post -marketing surveillance data from 1997 to 2005 from 
the US Vaccine Adverse Event Reporting System (VAERS) reported 336 AEs for 1.1 million 
RABAVERT doses administered (0.03% of all doses) . Of these, 13 were neurological events 
(4% of all the AEs), but there was no pattern in the type or time of onset of symptoms to indicate 
a plausible association with the vaccine.25 RABAVERT is reactogenic in healthy people, causing 
local re actions (pain, induration , erythema ), lymphadenopathy, fever, myalgias, arthralgias, 
dizziness, nausea, headache , and rash . The following adverse reactions have been identified 
during post approval use of RabAvert: presyncope, syncope, palpitations, hot flush, extensive 
limb swelling and angioedema. Once reconstituted, RABAVERT contains processed bovine 
gelatin and trace amount s of chicken protein, neomycin, chlortetracycline, and amphotericin B; 
therefore, individuals with a history of allergy or hypersensitivity to these ingredients should be 
monitored for the possibility of allergic reactions following vaccination.  
ChAd Vecto r 
Administration of ChAd vectors can be associated with local reactions (pain, tenderness, redness, 
and swelling) and systemic symptoms including fatigue, myalgias, and arthralgias, or flu -like 
symptoms such as fever, chills, and headache.  
In recent clinic al trials of Ebola virus vaccine candidates using ChAd3 as the vaccine vector (a 
group C Ad, like ChAd155), there were no vaccine -related SAEs. Most AEs were mild (Grades 
1-3) and self -limited, resolving within 48 hours after vaccination. The most common s ystemic 
AEs were fatigue and headache. All abnormal lab values recorded during these studies were 
Grade 1, with the most common abnormalit ies being transient lymphopenia , anemia, or 
thrombocytopenia  that developed on Day 1 after vaccination, and which had resolved by Day 7 
after vaccination .9-12 Similar findings were reporte d for a novel ChAd3 -vectored HCV vaccine,14 
as well as multiple malaria vaccine candidates that used ChAd63 (a group E adenovirus) as the 
vaccine carrier.13 A small number of participants in each of the ChAd3 Ebola vaccine studies ( <5 
in each study ) developed asymptomatic prolongation of the activated partial thromboplastin time 
(aPTT) which resolved by the end of the follow -up period.9-12 In one of the trials , furth er 
investigation of the prolonged aPTT revealed induction of an antiphospho lipid antibody.12 
The ChAd155 vector being used in this trial has been previously tested in humans in a Phase 1 
trial of a novel RSV vaccine candidate.22 The vaccine dosages used in that study (low -dosage, 
5x109vp; high -dosage, 5x1010vp) were half of those proposed in this trial. Per the investigator’s 
brochure for ChAd155 -RG, i n that previous study, there were no vaccine -related SAEs, and the 
most common AEs were local injection site pain ( 100% of vaccine recipients vs. 5.3% of 
placebo recipients) , fatigue (50% of high -dosage (5x1010vp) vaccine recipients, only 1 subject or 
3% with Grade 3 fatigue)  and headache ( 34.5% of high-dosage vaccine recipients ). 
In recent studies of COVID -19 vaccines th at use an adenovirus vector, there were a small 
number of individuals who experienced rare but serious thrombotic events, including cerebral 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           28 
CONFIDENTIAL  
 venous sinus thrombosis, associated with thrombocytopenia . These events occurred after the 
Oxford -AstraZeneca COVID -19 vaccine, which uses a chimpanzee group E adenovirus  vector 
(ChAdOx1) , and the Johnson and Johnson/Janssen Biotech Inc’s COVID -19 vaccine, which uses 
a human group D  adenovirus  vector (Ad26) . The exact mechanism of this vaccine -induced 
thrombotic thromb ocytopenia is not fully understood , and may or may not be related to the 
adenovirus vectors used in th ese vaccines. There have been no thrombotic events identified i n 
published  studies of vaccines based on group C adenoviruses  (similar to Ch Ad155 ), though the 
number of subjects in the se studies w as significantly smaller th an the number of people who 
have received a n adenovirus -vector based  COVID -19 vaccine.  
Allergic Reaction  
Acute and potentially life -threatening allergic reactions are also possible. Up to 1 in 4 million 
vaccinated individuals may develop a serious allergic reaction, which can manifest as hives, 
angioedema, bronchospasm, tachycardia, or hypotension, and can usually be stopped by the 
administration of emergency medications by the study personnel. As with any vaccine, there is a 
very small chance of a fatal reaction, although researchers do not expect this to occur.  
Blood Draw and IM Injection  
Blood draws and IM injections may cause transient discomfort; fainting, which can mana ged by 
having the subject lie down; bruising, which can be prevented or lessened by applying pressure 
to the blood draw site for several minutes; nerve injury, which is very unlikely; and infection, 
which can be made extremely unlikely by using sterile tec hnique.  
Respiratory Virus  Testing  
Subjects may experience reactogenicity phenomena  following study vaccination  that overlap 
with symptoms of community -acquired respiratory viruses, including SARS -CoV -2. To 
accurately assess relatedness of systemic symptoms to study product, subjects who meet 
symptom criteria  (detailed in  the MOP) may undergo viral testing during the study. Sampling 
procedures (including, but not limited to, nasopharyngeal swab, nasal swab , or saliva sampling) 
may cause transient discomfort.  
Pregnancy  
It is unknown if these vaccines pose any risks to an unborn child. As such, women of 
childbearing potential (women who have not reached menopause >1 year) or who have not been 
surgically sterilized (tubal ligation, bilateral oophorectomy, or hysterectomy) must agree to use 
effective contraception for ≥28 days before the first vaccination through ≥60 days after the last 
vaccination.  
Breach of Confidentiality  
Subjects will be asked to provide personal health information (PHI). All attempts will be made to 
keep this PHI confidential within the limits of the law. However, there is a chance that 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           29 
CONFIDENTIAL  
 unauthorized persons will see a subject’s PHI. All records will be kept in a locked file cabinet or 
maintained in a locked room at the site. Electronic files will be pas sword protected. Only people 
who are involved in the conduct, oversight, monitoring, or auditing of this trial will be allowed 
access to this PHI. Any publications from this trial will not use information that will identify 
subjects by name. Organizations that may inspect and/or copy research records maintained at the 
site for quality assurance (QA) and data analysis include groups such as NIAID (or its designee) 
and FDA.  
A description of this trial will be available on http://www.ClinicalTrials.gov , as re quired by US 
Law. This web site will not include information that can identify subjects. At most, this web site 
will include a summary of the results.  
There may be other unknown risks, discomforts, or side effects.  
2.3.2  Known Potential Benefits  
As the ef ficacy of ChAd155 -RG in protecting against human rabies has not been proven, there 
are no known potential benefits to the subjects receiving ChAd155 -RG in this trial. Subjects who 
receive RABAVERT will be immunized against rabies. Society benefits if a saf e, tolerable, 
equally immunogenic vaccine for rabies which can be given in fewer doses than the currently 
available rabies virus vaccines, is ultimately developed as a result of this and other vaccine trials.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           30 
CONFIDENTIAL  
 3. OBJECTIVES AND OUTCOME MEASURES  
3.1. Study Objective s    
3.1.1.  Primary  
• Assessment of the safety, tolerability, and reactogenicity of one dose of ChAd155 -RG at 
5x1010vp per dose, or one or two doses of ChAd155 -RG at 1x1011vp per dose.  
• Comparison of the safety, tolerability, and reactogenicity of one or two doses of 
ChAd155 -RG, with three doses of RABAVERT.  
3.1.2.  Secondary  
• Assessment of serum rabies VNA levels by a standard, WHO -approved, RFFIT, as 
assessed by immune response kinetics (through approximately 12 months after first dose 
of vaccin e), seroconversion rat es, and peak GMT  in each treatment arm . 
3.1.3.  Exploratory (if applicable)  
• Quantification of circulating T -cell responses against RG by ex vivo IFN -gamma 
ELISpot.  
• Characterization of circulating CD4 and CD8 T -cell responses against RG at peak time 
point by multip arameter  ICS. 
• Comparison of durability of immune response to ChAd155 -RG and RABAVERT at 
approximately 3, 6, and 12 months after first dose of vaccine by each treatment arm 
tested . 
• Measure ment of  RG-specific memory B cells by ELISpot.  
• Measurement of an anti body response to the vaccine vector (ChAd155).  
3.2. Study Outcome Measures  
3.2.1.  Primary  
• Frequency and severity  of solicited injection site and systemic reactogenicity events from 
the time of each vaccination through Day 7 after each vaccination, in each treatment arm 
and overall . 
• Frequency and severity  of SAEs  considered study vaccine -related and reported at any 
time after the first vaccination through the end of the study , in each treatment arm and 
overall . 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           31 
CONFIDENTIAL  
 • Frequency and severity  of study vaccine -related lab AEs through Day 22 from the time of 
the first vaccination , in each treatment arm and overall . 
• Frequency and severity of  unsolicited study vaccine -related AEs from the time of the first 
vaccination through Day 28 after the last vaccination, in each treatment arm and overall . 
• Number of subjects with new onset of a chronic medical condition at any tim e after the 
first vaccination, in each treatment arm and overall.  
• Frequency and severity  of any SAEs  at any time after the first vaccination through the 
end of the study , in each treatment arm and overall . 
3.2.2.  Secondary  
• Proportion of subjects seroconverting t o rabies virus at each antibody time point  
(seroconversion is defined as VNA concentration  ≥0.5 IU/mL), in each treatment arm and 
overall.  
• GMT (as measured by rabies VNA using a standard, WHO -approved, RFFIT) at each 
antibody time point within each treatment arm . 
• Peak GMT (as measured by rabies VNA using a standard, WHO -approved, RFFIT; peak 
GMT is defined as highest GMT measured across all post -vaccination antibody time 
points) within each  treatment arm . 
3.2.3.  Exploratory  
• Frequencies of circulating T cel l responses against RG by ex vivo IFN -ELISpot.  
• Characteristics of circulating CD4 and CD8 T cell responses against RG by 
multiparameter ICS.  
• Magnitude and durability of RG -specific memory B cells by ELISpot.  
• GMT to ChAd155 vector at one month after first v accination  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           32 
CONFIDENTIAL  
 4. STUDY DESIGN  
This is a single -center, observer -blinded, Phase 1, dosage -escalation trial to evaluate the safety, 
tolerability, reactogenicity, and immunogenicity of ChAd155 -RG compared with RABAVERT 
in rabies virus -naïve healthy male and non-pregnant fe male adult subjects. There are 4  dose 
groups ( see Table  1). 
Subjects who have never received a licensed or investigational rabies virus vac cine, or an Ad -
based investigational vaccine, and who have never been exposed to a rabid animal will be 
eligible for enrollment.  
Since this is a dosage -escalation study, sentinel subjects will be used at each dosage level. The 
first four subjects will be randomized to Group A or D and will receive either a single dose of 
ChAd155 -RG at the lower dosage (5x1010vp, N=3) (followed by placebo on Days 8, 15, and 22) 
or RABAVERT (N=1) (on Days 1, 8, and 22, and placebo on Day 15) (see Table  1). These 
subjects will be monitored for safety, tolerability, and reactogenicity through day 7 after first 
study vaccination, and if no pre -defined halting rule is met (Section 9), then four additional 
sentinel subjects will be randomized to Group B or D and will receive either a single dose of 
ChAd 155-RG at the higher dosage (1x1011vp, N=3) (followed by placebo on Days 8, 15, and 22) 
or RABAVERT (N=1) (on Days 1, 8, and 22, and placebo on Day 15) (see Table  1). These 
subjects will be monitored for safety, tolerability, and reactogenicity through day 7 after first 
study vaccination. The SMC will then review the available safety, reactogenicity, AE, a nd lab 
data of all the sentinel subjects, and will decide if the remaining non -sentinel subjects should be 
enrolled.   
If the SMC recommends proceeding with the remainder of trial enrollment, eligible individuals 
will be enrolled and randomized to one of th e four dose groups (Groups A -D). To maintain 
blinding of study personnel conducting surveillance and assessment of AEs, subjects in these 
groups will receive 4 sequential injections, 1 ml per injection, in alternating arms, on the same 
schedule:  
• Subjects r andomized to Group A will receive ChAd155 -RG at the lower dosage 
(5x1010vp) on Day 1, then placebo injections on Day s 8, 15, and 22  
• Subjects randomized to Group B will receive ChAd155 -RG at the higher dosage 
(1x1011vp) on Day 1, then placebo injections on Days 8, 15, and 22  
• Subjects randomized to Group C will receive ChAd155 -RG at the higher dosage 
(1x1011vp) on Day s 1 and 15, and placebo injections on Day s 8 and 22  
• Subjects randomized to Group D will receive RABAVERT at the standard dose (1  mL) 
on Day s 1, 8, and 22, and a placebo injection on Day 15  
Vaccine preparation and administration will be unblinded. The investigational vaccine doses will 
be prepared just prior to administration to ensure that the volume of each injection is identical 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           33 
CONFIDENTIAL  
 between Grou ps A-D. Follow -up will be double -blinded, and the SMC will review the available 
safety, reactogenicity, AE, and lab data collected from all subjects for 15 days after the last 
vaccination and as needed.  
Subjects will be followed using a memory aid, face -to-face scheduled clinic visits, and safety lab 
monitoring as outlined in Section 7 and Appendix  A. Following enrollment and vaccination, 
safety lab blood samples will be collected on Days 2, 8, 16, and 22. Blood samples for 
immunologic assays will be collected on Days 1, 2, 8, 15, 16, 22, 29, 9 1, 181, and 3 81. The 
duration of each subject’s participation will be approximately 13 months, from recruitment to 
collection of data for safety and immunogenicity outcomes.  
This trial is expected to take approximately 30 months to complete, from initiation throu gh 
availability of a final report on the primary outcomes of safety and the secondary outcomes of 
VNA levels to RG. Exploratory outcomes are discussed in an addendum. A planned interim 
safety, reactogenicity, and immunogenicity analysis is detailed in Sect ion 11.3. 
4.1. Sub-studies (if applicable)  
No sub -studies are planned.  
 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           34 
CONFIDENTIAL  
 5. STUDY ENROLLMENT AND WITHDRAWAL  
Subject inclusion and exclusion criteria must be confirmed by a study clinician licensed to make 
medical diagnoses. No exemptions are granted on subject inclusion/exclusion criteria in DMID -
sponsored studies. Questions about eligibility will be directed toward the DMID Medical Officer.  
5.1. Subject Inclusion Criteria  
Subjects must meet all the following inclusion criteria to be eligible for th is trial, and for 
subsequent doses of vaccine/placebo : 
1. Must be a male or female aged 18 -49 years old  (inclusive) at the time of  first 
vaccination . 
2. Must be able to provide  written informed consent.  
3. Must have a body mass index (BMI) ≥18.5 and <35.0 kg/m2 
4. Must be in good health based on physical examination, vital signsa, medical history, 
safety labsb, and the investigator’s clinical judgment.  
aVital signs must be within the normal ranges in Appendix  C. If a subject has elevated 
systolic or diastolic blood pressure, subject may rest for 10 minutes in a quiet room  and the 
blood pressure may be retaken . 
bSafety  lab normal ranges will be those used by the reference clinical lab. Protocol -specific 
criteria for individual subjects are listed in criteria # 5. 
5. Must have acceptable* lab values within 28 days before enrollment.  
*Acceptable values include:  
-Hemoglobin: w omen >11. 6 g/dL, men >1 3.1 g/dL 
-White blood cells: >3, 700 but <1 0,900 cells/mm3 
-Absolute neutrophil count: ≥1,500 cells/mm3 
-Absolute lymphocyte count: ≥850 cells/mm3 
-Platelets: >1 39,000 but < 401,000 per mm3 
-Urine dipstick (clean urine sample): protein <1+, glucose negative  
-Alanine trans aminase  and aspartate trans amin ase (ALT, AST) <1. 1 x institutional upper 
limit of normal (ULN)  
-Total bilirubin <1. 1x institutional ULN  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           35 
CONFIDENTIAL  
 -Blood urea nitrogen (BUN) <1 x institutional ULN  
-Serum creatinine <1x inst itutional ULN  
-If lab screening tests are out of range, repeating them is permitted once, provided there is 
an alternative explanation for the out -of-range value.  
6. Women of childbearing potential * must have a negative serum pregnancy test at 
screening and negative urine pregnancy tests within 24 hours before each vaccination.  
*Women of non -childbearing potential, defined as postmenopausal (any age with 
amenorrhea for ≥12 months without other known or suspected cause for amenorrhea), 
or surgically sterile [hysterectomy, bilateral tubal ligation, bilateral oophorectomy, or 
successful Essure® placement (permanent, non -surgical, non -hormonal sterilization)] 
with documented confirmation test ≥3 months af ter the procedure), are not required to 
use contraceptive methods.  
7. Women of childbearing potential must use an acceptable method of contraception* from 
28 days before the first vaccination until ≥60 days after the last vaccination.  
*Acceptable methods of c ontraception include: prescription oral contraceptives, 
contraceptive injections, intrauterine device (IUD), implants, vaginal ring, double -
barrier method, contraceptive patch, male partner who had a vasectomy at least 6 
months prior to study enrollment,  abstinence (defined as refraining from heterosexual 
intercourse during participation in th is trial [from 28 days before the first vaccination 
until ≥60 days after the last vaccination]).  
8. Female subjects must agree to not donate eggs (ova, oocytes) from the  start of  screening 
until ≥60 days after the last vaccination.  
9. Male subjects who have not had a vasectomy * and are sexually active with a woman of  
childbearing potential must agree to use an acceptable method of contraception* *. 
*Men who have had a vasectomy must have had the procedure performed at least 6 
months prior to study enrollment  
*Acceptable methods of contraception  must be used from the first vaccination until >60 
days after the last vaccination, and  include: abstinence (defined as refraini ng from 
heterosexual intercourse with a female partner of childbearing potential during 
participation in th is trial [from 28 days before the first vaccination until ≥60 days after 
the last vaccination]; a double -barrier method, such as condom with spermici dal 
foam/gel/film/cream/suppository and partner with occlusive cap (diaphragm, 
cervical/vault caps); if the female partner is using an acceptable method of contraception 
(see Inclusion Criterion #7), a single -barrier method for the male subject is acceptab le. 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           36 
CONFIDENTIAL  
 10. Male subjects must agree to not donate sperm from the start of screening until ≥60 days 
after the last vaccination.  
11. Must be available and willing to participat e for the duration of th is trial .  
12. Must have a means to be contacted by telephone.  
5.2. Subject Exclusion Criteria   
Subjects meeting any of the following exclusion criteria at baseline will be excluded from study 
participation.  
1. Was ever vaccinated with a licensed or investigational rabies vaccine* or was diagnosed 
with rabies exposure, infec tion, or disease.  
*Includes RABAVERT and Imovax. Subject’s verbal history will suffice.  
2. Has a higher risk than the average US resident with regard to exposure to rabies, per the 
Rabavert package insert and rabies vaccination recommendations from the CDC*  
 
*People at high risk of exposure to rabies, such as veterinarians, animal handlers, rabies 
laboratory workers, spelunkers, and rabies biologics production workers.  
*People whose activities bring them into frequent contact with rabies virus or with 
possibly  rabid animals.  
*International travelers who are likely to come in contact with animals in parts of the 
world where rabies is common.  
 
3. Was ever vaccinated with a licensed or investig ational Ad vector or Ad vaccine.  
4. Is currently taking chloroquine or hydrox ychloroquine26 
5. Was diagnosed with laboratory -confirmed COVID -19 (PCR or antigen -based test) in the 
preceding 28 days . 
6. Positive serology for HIV antibody, HCV antibody, or Hepatitis B surface antigen  
(HBsAg) . 
7. Has known allergy or history of anaphylaxis or other serious adverse reaction to a 
vaccine or vaccine products*.  
*Including egg products, aminoglycosides, gelatin, sorbitol, tris (hydroxymethyl) -amino 
methane (THAM), or any of the constituents of the study vaccines.  
8. Has severe allergy or anaphylaxis to latex.  
9. Has an acute illness or temperature ≥38.0oC on Day 1*.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           37 
CONFIDENTIAL  
 *Subjects with fever or acute illness on the day of vaccination may be re -assessed and 
enrolled if healthy or only minor residual symptoms remain within 3 days.  
10. Female subjects who are pregnant or breastfeeding, or planning to become pregnant 
while  enrolled in th is trial  and at least 60 days after last vaccination.  
11. Has history of autoimmune disease, or clinically significant cardiac, pulmonary, hepatic, 
rheumatologic, or renal disease by history, physical examination, and/or lab studies.  
12. Has history of malignancy other than squamous cell or basal cell skin cancer, unless there 
has been surgical excision that is considered to have achieved cure*.  
*Subjects with a history of skin cancer must not be vaccinated at the previous tumor site.  
13. Has know n or suspected congenital or acquired immunodeficiency, or recent history or  
current use of immunosuppressive therapy*.  
*Anti -cancer chemotherapy or radiation therapy within the preceding 6 months, or long -
term (≥2 weeks within the previous 3 months) syste mic corticosteroid therapy (at a 
dosage of ≥0.5 mg/kg/day). Intranasal or topical prednisone (or equivalent) are allowed.  
14. Is post -organ and/or stem cell transplant, whether or n ot on chronic immunosuppressive 
therapy.  
15. Had major surgery (per the investigato r’s judgment) within 4 weeks before study entry or 
planned major surgery during th is trial . 
16. Has history of diabetes mellitus type 1 or type 2, including cases controlled with diet 
alone.  
*Note : history of isolated gestational diabetes is not an exclusion c riterion.  
17. Has history of thyroidectomy, or thyroid disease requiring medication in the last 12 
months.  
18. Has history of hypertension, even if medically controlled.  
*Note : Vital signs must be normal by  protocol toxicity grading scale . In the event of an 
abnor mal heart rate or blood pressure due to physiological variation or activity, the 
subject may rest for 10 minutes in a quiet room, and then blood pressure and/or heart 
rate re -measured. Repeated vital signs may be used to determine eligibility.  
19. Received liv e attenuated vaccines from 30 days before first vaccination until 30 days 
after final vaccination. * 
*Not including licensed  or authorized  COVID -19 vaccines  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           38 
CONFIDENTIAL  
 20. Received killed or inactivated vaccines from 14 days before first vaccination until 30 
days after final vaccination. * 
*Not including licensed or authorized COVID -19 vaccines  
21. Received experimental therapeutic agents within 3 months before first vaccination or 
plans to receive any experimental therapeutic agents during th is trial .* 
*That that in th e opinion of the investigator would interfere with safety or 
immunogenicity assessments . 
22. Is currently participating or plans to participate in another clinical study which would 
involve receipt of the following:*  
* An investigational product, blood drawing, or an invasive medical procedure that 
would require administration of anesthetics, intravenous (IV) dyes, or removal of tissue 
during th is trial  and, in the opinion of the investigator , would interfere with safety or 
immunogenicity assessments . 
-Includes endoscopy, bronchoscopy, and administration of IV contrast.  
23. Received blood products or immunoglobulin in the 3 months before study entry or 
planned use during th is trial . 
24. Donated a unit of blood or blood products within 8 weeks before Day 1 or plan s to donate 
blood or blood products during th is trial . 
25. Has major psychiatric illness in the past 12 months that in the opinion of the investigator 
would preclude participation.  
26. Has current alcohol use or current or past abuse of recreational or narcotic dr ugs by 
history as judged by the investigator to potentially interfere with study adherence.  
27. Has a history of chronic urticaria.  
28. Has tattoos, scars, or other marks on both deltoid areas which would, in the opinion of the 
investigator, interfere with assessm ent of the vaccination site.  
29. Is a site employee* or staff who are paid entirely or partially by/through the OCRR 
contract for th is trial, or staff who are supervised by the Principal Investigator (PI) or sub -
investigators.  
*Including the PI, sub-investigators listed on Form FDA 1572 or Investigator of Record 
Form.  
30. In the opinion of the investigator cannot communicate reliably, is unlikely to adhere to 
the requirements of th is trial , or has any condition which would limit the ability to 
complet e this trial . 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           39 
CONFIDENTIAL  
 31. Has history of Guillain -Barre syndrome, meningitis, encephalitis, neuroparalysis, 
transient paralysis, myelitis, retrobulbar neuritis, multiple sclerosis, vertigo, or visual 
disturbances.  
32. Has a history of arterial or venous thrombosis , or thr ombocytopenia that required medical 
attention . 
5.3. Treatment Assignment Procedures   
5.3.1.  Randomization Procedures  
The list of randomized vaccine assignments will be prepared by statisticians at The Emmes 
Corporation and included in the enrollment module of The Emm es Corporation’s Internet Data 
Entry System (IDES). IDES will assign each subject a vaccine code from the list after 
demographic and eligibility data have been entered into it. A designated individual at the site will 
be provided with a vaccine key, which links the vaccine code to the vaccine  assignment, which 
will be kept in a secure place.  
Subjects in sentinel group 1 will be randomized 3:1 to either dose Group A or D. If no halting 
criteria are met through  Day 8, then subjects in sentinel group 2 will be randomized 3:1 to either 
dose Group B or D. The SMC will review safety dat a from both sentinel groups through  Day 15 
for sentinel group 1 ( Day 8 for sentinel group 2), and if they approve, then the remaining  non-
sentinel subjects will be enrolled and randomized to the 4 dose groups  (Groups A -D). 
Instructions for use of the enrollment module are included in the IDES User’s Guide. Manual 
back -up randomization procedures are provided in the Manual of Procedures (MOP ) for use in 
case the site temporarily loses access to the Internet or the online enrollment system is 
unavailable.  
Study product will be administered by an unblinded administrator. The subjects , the study 
personnel who perform study assessments after administration, data entry personnel at the site, 
and laboratory personnel performing immunologic assays will be blinded  to vaccine assignment.   
The SMC may receive data in aggregate and presented by dose group, but without the dose 
group (or dose level) identified. The SMC may be unblinded to individual vaccine  assignments, 
as needed, to adequately assess safety issues. R efer to the MOP for unblinding procedures.  
5.3.2.  Masking Procedures  
Investigators and study personnel performing any study -related assessments following 
vaccin ation will be blinded  to study vaccine . Syringes will be labeled with an overlay/blinding 
tape containing the subject ID, and the treatment number from the treatment key, and expiration 
time for the syringe, and provided to the unblinded vaccine administrator. Lab personnel 
performing assays wil l be blinded to all subjects.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           40 
CONFIDENTIAL  
 The randomization scheme will be generated by the Statistical and Data Coordinating Center 
(SDCC ) and provided to unblinded study personnel (i.e., pharmacists preparing  vaccin es, clinical 
staff administering vaccines ) at the s ite. 
The unblinded vaccine  administrator  will be  credentialed to administer vaccines, but  will not be 
involved in study -related assessments , subject contact , or data collection following vaccination . 
5.3.3.  Reasons for Withdrawal  and Discontinuation of Study Product Administration  
Subjects may voluntarily withdraw their consent for study participation at any time without 
penalty or loss of benefits to which they are otherwise entitled.  A study subject will be 
discontinued from participation in the trial if any of the following reasons occur before dosing:  
• Request by the subject to terminate participation  
• Lost to follow -up 
• As deemed necessary by the site principal investigator or appropriate sub -investigator fo r 
noncompliance or other reasons.  
• New information becomes available that makes further participation unsafe . 
An investigator may also withdraw a subject from receiving subsequent doses of vaccine  for any 
reason. Follow -up safety and immunogenicity evaluati ons will be conducted, if the subject 
agrees. The reasons m ay include, but are not limited to , the following:  
• Subject no longer meets eligibility criteria  
• Subject meets individual halting criteria ( listed in  Section  9.5) 
• Subject becomes noncompliant  
• Subject develops a m edical disease or condition, or new clinical finding(s) for which 
continued participation, in the opinion of the investigator might compromise the safety of 
the subject, interfere with the subject's successful completion of this trial, or interfere 
with th e evaluation of responses  
• Female s ubject becomes pregnant  
• Male subject if his female partner becomes pregnant  
• Determined by a physician’s discretion to require additional therapy not indicated in the 
protocol to ensure the subject’s health and well -being  
If a subject withdraws or is withdrawn before completing this trial, the reason for this decision 
will be recorded in the electronic case report form (eCRF). The investigator will be explicit 
regarding study follow -up (e.g. , safety follow -up) that might be carried out despite the fact the 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           41 
CONFIDENTIAL  
 subject will not receive further vaccine . If the subject consents, every attempt will be made to 
follow all AEs through resolution. The procedures that collect safety data for the purposes o f 
research will be inclusive in the original ICF or the investigator may seek subsequent informed 
consent using an IRB/IEC -approved ICF with the revised procedures.  
The investigator will inform the subject that data already collected will be retained and a nalyzed 
even if the subject withdraws from this trial.  
5.3.4.  Handling of Withdrawals  and Discontinuation of Administration    
The primary reason for withdrawal from this trial will be recorded on the Study Status form. If a 
subject discontinues product administration, the primary reason will be recorded on the 
Discontinuation of Treatment form . Subjects will be asked to complete the Early Termination 
Visit  (procedures listed in Section 7.6). 
Although subjects have the right to withdraw from th is trial  at any time or may be withdrawn by 
the site PI or approp riate sub -investigator at any time, those subjects who received only one dose 
of vaccine  will be asked to remain in this trial for follow -up safety and immunogenicity 
assessments. Safety assessments may be done by phone call, rather than in person, if this  is the 
only means available of obtaining safety information. Subjects who withdraw from th is trial  will 
be asked to provide blood samples for immunogenicity testing and exploratory endpoints. See 
the MOP for alternate follow -up requirements.  There will be no exceptions to the planned dose 
schedule.  
Every attempt will be made to follow all AEs, includin g solicited injection site and systemic 
reactions, unsolicited non -serious AEs, and SAEs , ongoing at the time of early withdrawal 
through resolution as per applicable collection times defined for specific type s of AEs. 
If subjects fail to appear for a safe ty follow -up assessment, extensive effort (i.e., three 
documented contact attempts via phone calls, e -mails, etc., made on separate occasions and 
followed by a certified letter) will be made to locate or recall them, or at least to determine their 
health s tatus. These efforts will be documented in the subject’s records.  
Subjects may be replaced following written approval from the sponsor  (detailed in next sub -
section) . Subjects who withdraw, or are withdrawn or terminated from this trial, or are lost to 
follow-up after signing the ICF and randomization but before receipt of the first dose of vaccine  
will be replaced.  
5.3.5.  Subject Replacement  
Subjects who withdraw, or are withdrawn or terminated from this trial, or are lost to follow -up 
after signing the ICF and r andomization, but before receipt of any doses of vaccine will be 
replaced.  Subjects who do not receive protocol -specified subsequent  doses of vaccin e may be 
replaced following written approval of the sponsor ( Section 5.3). Subjects who are discontinued 
or withdraw from th is trial  will be replaced irrespective of the dose group to which they were 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           42 
CONFIDENTIAL  
 assigned, and replacement subjects will be assigned according to usual enrollment/randomization 
procedures . 
5.3.6.  Termination of Study  
If this trial  is prematurely terminated by the sponsor, an y regulatory authority, or the investigator 
for any reason, the investigator will promptly inform the subjects and assure appropriate therapy 
or follow -up for the subjects, as necessary. The investigator will provide a detailed written 
explanation of the t ermination to the IRB/IEC.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           43 
CONFIDENTIAL  
 6. STUDY INTERVENTION/INVESTIGATIONAL 
PRODUCT    
6.1. Study Product Description  
 
ChAd155 -RG Vaccine  
The ChAd155 -RG Vaccine consists of a replication -defective group C ChAd , ChAd155, 
expressing RG under the control of the CMV promoter. The RG sequence cloned into the 
ChAd155 vector is a medoid, a natural viral strain with the highest average percent of amino acid 
identity among all RG sequences annotated in the NCBI database . The selected RG (NCBI strain 
AGN94271) shares an average 94% percent identity to the R Gs in current vaccines.  
RABAVERT Vaccine  
The RABAVERT Vaccine is an inactivated , purified chick embryo cell vaccine  (PCECV ). It 
consists of lyophilized rabies virus (strain Flury LEP) that has been propagated in chicken 
fibroblasts, inactivated with β-propiolactone, and concentrated and purified by 
centrifugation Placebo  
The placebo is 0.9% Sodium Chloride, USP injection.  
 
6.1.1.  Acquisition  
ChAd155 -RG and RABAVERT will be provided by GSK Vaccines under agreement with 
DHHS , and  will be supplied through DMID CMS to the site before  the start of this trial upon 
request and with prior approval from DMID. Should the site PI require additional vaccine  during 
this trial, further instructions are provided in the MOP.  
Placebo  
Normal saline will be used as the placebo, and will be provided by DMID Clinical Materials 
Services (CMS, Fisher BioServices  
6.1.2  Formulation, Packaging, and Labeling  
 
ChAd155 -RG Vaccine  
The purified ChAd155 -RG bulk drug substance is processed as follows  to obtain drug product: 
Purified ChAd155 -RG drug substance is diluted in buffer A 195 (Tris base 10mM, NaCl 75 mM, 
L-Histidine 10mM, MgCl 2 1 mM, EDTA 0.1 mM, Polysorbate 80 0.02% (w/v), sucrose 5% 
(w/v), ethanol 0.5% (v/v), HCl for adjustment to pH 7.4).  It then undergoes sterile filtration and 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           44 
CONFIDENTIAL  
 is then transferred into final containers. The ChAd155 -RG drug product  is a liquid formulation 
contained in vials. It is presented  as a sterile suspension in a 3 -mL clear glass, stoppered vial, 
with a 1-mL extractable volume (nominal single dose).  
The vaccine is suppled as a single 1mL -dose and is formulated without preservative.  
The study product will  be labelled according to manufacturer specifications or regulatory 
specifications and include the statement “Caution: New Drug -Limited by Federal Law to 
Investigational Use.”  
 
RABAVERT Vaccine23 
RABAVERT  is a freeze -dried vaccine obtained by growing the fixed -virus strain Flury LEP in 
primary cultures of chicken fibroblasts. The virus is inactivated with β -propiolactone, processed 
by zonal centrifugation , and  then lyophilized after addi ng a stabilizer solution consist ing of 
buffered polygeline and potassium glutamate. One dose of reconstituted vaccine contains ≤12 
mg polygeline (processed bovine gelatin), ≤0.3 mg human serum albumin, 1 mg potassium 
glutamate , and 0.3 mg sodium EDTA. Small quantities of bovine serum (originating from the 
US, Australia, and New Zealand) are used in the cell culture process; ovalbumin content is ≤3 
ng/dose (1 mL), based on ELISA. Antibiotics (neomycin, ch lortetracycline, amphotericin B) 
added during cell and virus propagation are largely removed during subsequent steps in the 
manufacturing process ; thus, in the final vaccine, neomycin is present at ≤10 µg, 
chlortetracycline at ≤200 ng, and amphotericin B a t ≤20 ng per dose.  Rabavert is supplied in a 
package that contains a vial of the freeez -dried vaccine, a syringe containing 1 mL of sterile 
diluent (sterile water for injection), a sterile needle for reconstitution, and a sterile needle suitable 
for IM inj ection.  
The study product will be labelled according to manufacturer specifications or regulatory 
specifications and include the statement “Caution: New Drug -Limited by Federal Law to 
Investigational Use.”  
 
Placebo  
Placebo will be supplied as 0.9% Sodium C hloride Injection, USP which is a colorless, sterile, 
nonpyrogenic, isotonic solution of sodium chloride and water for injection (WFI). Each mL 
contains supplied chloride 9 mg. It contains no bacteriostatic, antimicrobial agent, or added 
buffer and is supp lied only in single -dose containers. The placebo, 0.9% Sodium Chloride, 
contains no preservatives. The solution may contain hydrochloric acid and/or sodium hydroxide 
for pH adjustment (pH 5.3 [4.5 to 7.0]).  
6.1.3 Product Storage and Stability    
 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           45 
CONFIDENTIAL  
 ChAd155 -RG Vaccine   
The vaccine product requires storage at ≤ -60˚C  
The stability of ChAd155 -RG final container lots will be followed for up to 60  months at the 
recommended storage condition of ≤ -60°C.  
RABAVERT Vaccine23 
RABAVERT contains no preservative , and  should be stored protected from light at 2°C to 8°C 
(36°F to 46°F). After reconstitution with the supplied sterile diluent ( water for injection) , the 
vaccine should  be used immediately  (as defined in the MOP) . The reconstituted vaccine is  a 
clear -to-slightly opalescent, colorless -to-slightly pink suspension. The vaccine may not be used 
after the expiration date given on package and container.  
Placebo  
0.9% Sodium Chloride, USP injection must be stored at 20ºC to 25ºC (68°F to 77ºF) [See USP 
Controlled Room Temperature; excursions between 15°C and 30°C (59°F and 86°F) are 
permitted]. See protocol -specific MOP for further instructions. . 
Additional information  
All vaccines  will be stored in the site research pharmacy. The temperature of the storage unit will 
be continuously monitored and recorded during th is trial per the site ’s SOPs , and documentation 
will be maintained. If the temperature fluctuate s outside of the required range, the affected study 
product (s) will be quarantined at the correct storage temperature and labeled “Do Not Use ” (until 
further notice). The pharmacist will alert the site PI and study coordinator if the temperature 
fluctuates  outside of the required range. I f the temperature fluctuates outside of the required 
range, including accidental deep -freezing or disruption of the cold chain, the affected vaccine (s) 
will not be administered. The site PI or responsible person should imme diately contact the 
DMID Product Support Team at DMIDProductSupportTeam@niaid.nih.gov and DMID Clinical 
Project Manager (CPM) for further instructions before any additional study vaccin es are 
administered. Based on the information collected, DMID and/or the manufacturer will determine 
whether the affected vaccine (s) can be used. If it cannot be used, the site will receive specific 
instructions on how to return the affected vaccine (s) to DM ID CMS  or destroy it on site. 
Additional instructions for quarantine are provided in the MOP.  
Stability studies to support study vaccine  storage conditions have been conducted. The sponsor 
will continue to monitor the stability of the vaccines  and will al ert the site if a lot is nearing the 
end of its anticipated shelf life.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           46 
CONFIDENTIAL  
 6.2. Dosage, Preparation and Administration of Study 
Intervention/Investigational Product  
ChAd155 -RG Investigational Vaccine   
The ChAd155 -RG candidate vaccine is formulated without preserv ative and is presented as a 
sterile suspension in a 3 -mL clear glass, stoppered vial, at a concentration of 1.3x1011vp/mL.  
The dosages of ChAd155 -RG to be used in this study are: 5x1010vp (low dose) and 1x1011vp 
(high dose). These dosages will be prepared at site’s pharmacy . See the MOP for detailed 
information on the preparation, labeling, storage, and administration of the ChAd155 -RG 
investigational vaccine. Vaccine preparation will be performed by the site pharmacist on the 
same day of vaccine a dministration . 
On vaccination day s, vaccines will be allowed to thaw to room temperature and administered 
within 1 hour. The vaccine is administered IM over the deltoid region of the arm.  Qualified 
medical person nel will wear gloves. During administration of the vaccine, medication and 
resuscitation equipment will be immediately available for the management of anaphylaxis.  
In order to minimi ze dissemination of the recombinant vectored vaccine virus into the 
environment, the inoculation site will be covered with a dressing after immuni zation. This should 
absorb any virus that may leak out through the needle track. The dressing will be removed from 
the injection site after 30 minutes and will be disposed as Genetically Modified Organisms 
(GMO) waste by autocla ving, in accordance with the relevant SOP and current standard US 
practice.  
RABAVERT Vaccine23 
 
The RABAVERT Vaccine will be prepared as outlined in the package insert. Additional 
information: See the MOP for detailed information on the preparation, labeling, storage , and 
administration of study vaccine for each group. Vaccine preparation will be per formed by the 
site pharmacist on the same day of vaccine administration.  
Visually inspect the ChAd155 -RG Vaccine , RABAVERT Vaccine , and admixture vials , upon 
receipt and before  use. If the vaccine (s) appear(s) to be damaged, contaminated , or discolored, 
contain visible particulate matter, or if there are any concerns regarding its integrity, do not use 
the affected vaccine (s). Instead, quarantine it at the correct storage temperature  and label it “Do 
Not Use ” (until further notice). The site PI or responsible person should immediately contact the 
DMID Product Support Team at DMIDProductSupportTeam@niaid.nih.gov and DMID C PM for 
further instructions before any additional vaccin es are administered. Based on the information 
collected, DMID and/or t he manufacturer will determine whether the affected vaccine (s) or 
admixture can be used. If it cannot be used, the site will receive specific final disposition  
instructions from DMID (e.g. how to return the affected vaccine (s) to DMID C MS or destroy it 
on site). If the vaccine(s) or admixture is unusable, the site pharmacist will prepare another dose 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           47 
CONFIDENTIAL  
 of admixture vial.  Replacement vials may be requested by contacting DMID. Additional 
instructions for quarantine and DMID contact information are provided in t he MOP.  
Study vaccine administration will be performed by a n unblinded vaccine  administrator who is 
credentialed to administer vaccines , but will not  participate in dose preparation, and may not be 
involved in study -related assessments , subject contact , or data collection after vaccine 
administration. On the assigned  dosage  days, each dose of vaccine will be administered to 
subjects via a single IM injection (depending on group assignment and/or randomization) in the 
preferred arm.  The dose administration schedule is as follows:  
• Subjects randomized to Group A will receive ChAd155 -RG at the lower dosage 
(5x1010vp) on Day 1, then placebo injections on  Days 8, 15, and 22  
 
• Subjects randomized to Group B will receive ChAd155 -RG at the higher dosage 
(1x1011vp) on Day 1, then placebo injections on Day s 8, 15, and 22  
 
• Subjects randomized to Group C will receive ChAd155 -RG at the higher dosage 
(1x1011vp) on Day s 1 and 15, and placebo injections on Day s 8 and 22  
 
• Subjects randomized to Group D will receive RABAVERT at the standard dose (1mL) on 
Days 1, 8, and 22, and a placebo injection on Day 15  
 
Placebo  
Gently invert the normal saline vial 5 to 7 times.  Using aseptic technique, puncture the septum 
top of the saline vial with a 1 -inch, 23 - or 25 -gauge disposable, sterile needle attached to a 1 -mL 
disposable, sterile syringe. Withdraw 1.0 mL from t he saline vial. The prepared saline dose will 
be allowed to store at room temperature and administered within 1 hour. The dose will be 
administered IM over the deltoid region of the preferred arm.  
 
6.3. Accountability Procedures for the Study Investigational Pr oduct(s)  
Study vaccines  will be stored and shipped from DMID CMS  to the site. Once received, vaccines  
will be stored in and dispensed by the Emory Hope Clinic Investigational Pharmacy. Unused 
vaccines  will be returned to DMID CMS .  
The FDA requires accounting for the disposition of all investigational products.  After receipt of 
the study vaccine, the site principal i nvestigator is responsible for ensuring that a current record 
of product disposition is maintained and product is disp ensed only at an official study site by 
authorized personnel as required by applicable regulations and guidelines. Records of product 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           48 
CONFIDENTIAL  
 disposition, as required by federal law, consist of the date received, date administered, quantity 
administered, and the s ubject number to whom the study product was administered.  
As this is a blinded study, the site principal investigator  will delegate this responsibility to the 
unblinded site pharmacist.  The unblinded site  Pharmacist will be responsible for maintaining 
accurate records of the shipment and dispensing of the investigational product. The pharmacy 
records will be available for inspection by the DMID monitoring contractors, and is subject to 
inspection by a regulatory agency (e.g., FDA) at any time. An assigned  Study Monitor will 
review the pharmacy records.  
Unused reconstituted vaccine s will be stored at [ 2oC-8oC for RABAVERT, ≤ -60 oC for 
ChAd155 -RG] in the Investigational Pharmacy until trial accountability is completed. At trial 
termination, all unused vaccines  will be disposed in accordance with the MOP following their 
complete accountability and monitoring.  
6.4. Concomitant Medications/Treatments    
Administration of any medications, therapies, or vaccines will be documented on the appropriate 
eCRF . Concomitant medications will include all current medications and non -study vaccinations 
taken within 30 days before  signing the ICF through approximately 28  days after the last study 
vaccination, and for new -onset chronic medical conditions  through approximately 12 months 
after the last vaccination for each subject. Subjects who do not receive all vaccinations will have 
concomitant medications collected throu gh approximately 28 days after the last vaccination, or 
early termination, whichever occurs first. Prescription and over -the-counter drugs will be 
included as well as herbals, vitamins , and supplements.  
Use of new medication should prompt evaluation for th e presence of a new diagnosis of chronic 
medical disease or condition.  
Medications that might interfere with the evaluation of the study vaccines  should not be used 
during the trial unless absolutely necessary. Medications in this category include the proh ibited 
medications per the subject exclusion criteria (see Section 5.2, #3 and #11 ). In addition, the site 
PI or appropriate sub -investigator may identify other medications that should not be used due to 
a risk to subject safety or assessment of reactogenicity and  immunogenicity. Use of medications 
as prophylaxis before  study vaccination is prohibited.  
To the sponsor’s knowledge, there are no known drug -vaccine interactions with the study 
vaccines  and subjects are not being asked to discontinue current medications not listed in the 
exclusion criteria. In the event medical conditions dictate use of medications, subjects are 
encouraged to obtain adequate care, comply with the course of therapy as prescribed by their 
physician , and inform the Investigator as soon as pr acticable. Details of all medications taken 
during this trial (date, brand or generic name) will be recorded.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           49 
CONFIDENTIAL  
 7. STUDY SCHEDULE  
7.1. Recruitment   
Subjects will be recruited through : posting of IRB -approved flyers  on the Emory University 
campus; use  of social media, list serves (such as CDC , ID, and Vaccine Dinner Club) , and 
clinical trial recruitment websites ; a HIPAA -compliant clinical trials database to identify subjects 
of previous trials at the Hope Clinic who  have agreed to future contact ; presentat ions by Hope 
Clinic faculty at various University and community venues ; and volunteer word -of-mouth.  
If subjects are agreeable and interested,  they will be screened initially over the phone for general 
eligibility criteria and their PHI will be saved in a locked cabinet  in a secure  office of the study 
coordinator/recruit er. When appropriate, an a ppointment at the Hope Clinic is then scheduled for 
an in-person cl inic visit. Research staff will  then obtain written consent per the standard 
informed consent pro cess before conducting protocol -specific screening activities.  
7.2. Screening    
 
7.2.1.  Visit 00A, Day -28 to -1, 1st Screen, Clinic Visit  
 
• Potential subjects will be screened for eligibility -28 to -1 days before  administration of 
the first study vaccination. If a subject has a positive symptom screen  prior to the visit 
(per the MOP), subsequent procedures  will be based on whether viral testing was pursued 
by the subject and the test result  if applicable  (as outlined in the MOP).  
 
• The following activities will be performed  at the 1st Screen : 
• Begin the informed consent process. Provide subjects with a description of this trial 
(purpose and study procedures) and ask them to read the ICF. Provide an opportunity to 
the potential subject to ask questions. If she/he wishes to proceed with participation, the 
ICF should be signed  before  performing any screening procedures.  
• Review eligibility criteria.  
• Interview subjects to collect medical history, and recent (i.e., within past 30 days) travel, 
blood donation  (8 weeks prior to Day 1) , vaccination history , and pre -study medication 
use. Interview of subjects is sufficient for obtaining medical history. Solicitation of 
medical records from the subject’s primary care provider is not required.  
• Review subject s’ concomitant medications taken within 90 days before  signing the ICF. 
• Obtain vital signs, including oral temperature, pulse, and blood pressure to assure 
eligibility.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           50 
CONFIDENTIAL  
 • Measure  height and weight and calculate BMI.  
• Perform a full physical examination , including the following organs and organ systems: 
general a ppearance, head/eyes/ears/nose/throat (HEENT), neck, lungs, heart, abdomen, 
extremities, musculoskeletal, lymph nodes, skin, and nervous system . All physical exams 
will be done by a clinician licensed to make medical diagnoses and listed on Form FDA 
1572 a s site PI or sub -investigator.  
• Collect venous blood for WBC s, hemoglobin, platelets, absolute neutrophil count, 
absolute lymphocyte count, ALT, AST, total bilirubin, BUN, creatinine, HIV -1/2 
antibody, H BsAg , and HCV  antibody.  
• Collect serum for pregnancy test from all female subjects of childbearing potential.   
• Collect urine for dipstick glucose and protein . 
• The overall eligibility of the subject to participate in th is trial  will be assessed once all 
screening test values and r esults of any other required evaluations are available. Subjects 
who qualify for inclusion will be contacted and scheduled for enrollment and first 
vaccination within 28 days.   
7.2.2.  Visit 00B, Day -28 to -1, 2nd Screen, Clinic Visit  – This visit may occur to repeat 
a screening assessment whose initial result is thought to be temporary  OR for 
subjects previously identified as eligible but who are out of window for 
enrollment  
 
• Subjects may return for a 2nd Screen for eligibility  -28 to -1 days before  administration of 
the first study vaccination. If a subject has a positive symptom screen  prior to the visit 
(per the MOP), subsequent procedures  will be based on whether viral testing was pursued  
by the subject  and the test result if applicable (as outlined in the MOP).  
• Review eligibility criteria, including results of available clinical screening lab 
evaluations . 
• Review medical history and any updates obtained by interview of subjects since the 
screening visit (Visit 00A) to assure continued eligibility.  
• Review all concomitant medications recorded on the appropriate eCRF . 
• Obtain vital signs including oral temperature, blood pressure, and pulse  to assure 
eligibility.  
• Measure  height and weight and calculate BMI.  
• Perform a targeted physical examination, if needed.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           51 
CONFIDENTIAL  
 • Collect blood and urine for safety labs , if needed .  
 
7.3. Enrollment/Baseline  
7.3.1.  Visit 01, Day 1, Enrollment and First Vaccination  
• If a subject has a positive symptom screen  prior to the visit (per the MOP), subsequent 
procedures  will be based on whether viral testing was pursued by the subject and the test 
result , if applicable  (as outlined in the MOP).  
• Reconfirm subject’s willingness to participate before  performing a ny study procedures, 
including the first vaccination.  
• Review e ligibility criteria, including results of all clinical screening lab evaluations, with 
subjects before  the first vaccination to assure continued eligibility. * If the initial safety 
labs are >28 days old, these tests will need to be repeated and results obtained before  
first vaccin ation  (see Section 7.2). 
• Review medical history and any updates obtained by interview of subjects since the  last 
screening visit (Visit 00 A or, if performed, Visit 00 B) to assure continued eligibility.  
• Review all con comitant medications and recent (within 28 days) vaccinations with 
subjects before  the first vaccination for accuracy and completeness. Any new medications 
taken since the last screening visit (Visit 00 A or, if performed, Visit00 B) will be recorded 
on the appropriate eCRF  and assessed for continued eligibility.  
• Assess all AE/SAEs and new onset chronic medical conditions and record them on the 
appropriate eCRF.  
• Obtain v ital signs including oral temperature, blood pressure, and pulse before  the first 
vaccination. Perform a  targeted physical examination  as needed before  the first 
vaccination, if indicated based on review of complete medical history and updates 
obtained by interview of subjects since the last screening visit (Visit 00 A or, if 
performed, Visit 00 B). 
• Perform a  urine pregnancy test  within 24 hours before  first vaccination  on all female 
subjects of childbearing potential. Results must be negative and known befor e enrollment 
and first vaccination . 
• Collect  blood samples  for baseline immunogenicity  (RFFIT assay) , memory B cell  
(MBC) , and T cell assays  (IFN -gamma ELISPOT) before vaccination . 
• Collect blood samples for developer assays before vaccination.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           52 
CONFIDENTIAL  
 • Collect blood samples for PBMCs for future use, if the subject has provided consent.  
• Subjects will be enrolled in Advantage EDCSM and randomly assigned before  the first 
vaccination.  
• Perform p re-administration reactogenicity assessments before  the first vac cination to 
establish baseline. Subjects will then receive a single dose of vaccine  via IM injection 
into the deltoid muscle of the preferred arm. The site of injection (right or left arm) and 
time of administration will be recorded on the appropriate eCRF .   
• Observe s ubjects in the clinic for ≥30 minutes after vaccination to monitor for any acute 
reactions.  
• Evaluate the vaccination site and assess for reactogenicity and AE/SAEs for ≥30 minutes 
after vaccination and before  discharge from clinic and record on the appropriate CRF . 
• Subjects will enter their reactogenicity information on a memory aid. Subjects will be 
provided a thermometer , ruler  and memory aid and will record daily oral temperature, 
solicited injection site and systemic reactions, any unsolicited AEs, and concomitant 
medications. Subjects will be asked to bring their  memory aid with them at their next 
study visit.  
7.4. Follow -up 
7.4.1.  Visit  02, Day 2 (window: +2 days)  
 
• If a subject has a positive symptom screen  prior to the visit (per the MOP),  viral testing 
may be performed during this study visit  with a research -based assay    
• Obtain interim medical history, including an assessment for new medical conditions by 
interview of subjects and note any changes since the previous clinic visit.  
• Record a ll concomitant medications on the appropriate eCRF . 
• Obtain vital signs including oral temperature, blood pressure, and pulse.  
• A tar geted physical examination will be performed, if needed, by a study clinician 
licensed to make medical diagnoses and listed on Form FDA 1572 as the site PI or sub -
investigator, if indicated based on review of complete medical history.  
• Examine vaccination s ite for local reactions and determine whether information recorded 
by subjects on the memory aid conforms to examination.  
• Collect b lood for safety labs  (chemistry, hematology)  and developer assays.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           53 
CONFIDENTIAL  
 • Assess a ll AE/SAEs and new onset chronic medical condition s and record  them  on the 
appropriate eCRF . 
 
7.4.2.  Visit 0 3, Day 8 (window: +2 days) , Second Vaccination  
 
• If a subject has a positive symptom screen  prior to the visit (per the MOP),  viral testing 
may be performed during this study visit  with a research -based assay    
• Obtain interim medical history, including an assessment for new medical conditions by 
interview of subjects and note any changes since the previous clinic visit or phone call.  
• Review eligi bility criteria  with subjects , and review  results of all safety lab evaluations, 
before vaccination to assure continued eligibility  for vaccination . 
• Record a ll concomitant medications on the appropriate eCRF . 
• Perform a  targeted physical examination, if ind icated based on review of complete 
medical history.  
• Obtain vital signs including oral temperature, blood pressure, and pulse.  
• Examine vaccination site for local reactions and determine  information recorded by 
subjects on the memory aid conforms to examination.  
• Collect b lood for safety  labs (chemistry, hematology),  immunogenicity  (RFFIT assay) , 
and developer assays  before vaccination . 
• Perform a urine pregnancy test within 24 hours before second vaccination on all female 
subjects of childbearing poten tial. Results must be negative and known before second  
vaccination.  
• Perform pre -administration reactogenicity assessments before the second vaccination to 
establish baseline. Subjects will then receive a single dose of vaccine via IM injection 
into the del toid muscle of the arm opposite to that of the first injection . The site of 
injection (right or left arm) and time of administration will be recorded on the appropriate 
eCRF.   
• Observe subjects in the clinic for ≥30 minutes after vaccination to monitor for  any acute 
reactions.  
• Evaluate the vaccination site and assess for reactogenicity and AE/SAEs for ≥30 minutes 
after vaccination and before discharge from clinic and record on the appropriate CRF.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           54 
CONFIDENTIAL  
 • Subjects will enter their reactogenicity information on a me mory aid. Subjects will be 
provided a thermometer , ruler  and memory aid and will record daily oral temperature, 
solicited injection site and systemic reactions, any unsolicited AEs, and concomitant 
medications. Subjects will be asked to bring their memory aid with them at their next 
study visit.  
• Assess a ll AE/SAEs and new onset chronic medical conditions  and record  them  on the 
appropriate eCRF . 
 
7.4.3.  Visit 0 4, Day 15 (window: +2 days) , Third Vaccination   
 
• If a subject has a positive symptom screen  prior to the visit (per the MOP),  viral testing 
may be performed during this study visit  with a research -based assay    
• Obtain interim medical history, including an assessment for new medical conditions by 
interview of subjects and note any changes since th e previous clinic visit or phone call.  
• Review eligibility criteria with subjects, and review results of all safety lab evaluations, 
before vaccination to assure continued eligibility for vaccination.  
• Record a ll concomitant medications on the appropriate eCRF. 
• Perform a  targeted physical examination, if indicated based on review of complete 
medical history.  
• Obtain vital signs including oral temperature, blood pressure, and pulse.  
• Examine vaccination site for local reactions and determine whether information recorded 
by subjects on the memory aid conforms to examination.  
• Collect blood for immunogenicity  (RFFIT assay) , T cell  (IFN -gamma ELISPOT  and 
ICS), and developer  assays before vaccination . Blood for safety labs may be collected at 
the discretion of the investigator as specified in the MOP.  
• Collect blood samples for PBMCs for future use, if the subject has provided consent.  
• Perform a urine pregnancy test within 24 hours before third  vaccination on all female 
subjects of childbearing potential. Results must be negative and known before third 
vaccination.  
• Perform pre -administration reactogenicity assessments before the third  vaccination to 
establish baseline. Subjects will then receive a single dose of vaccine via IM injection 
into the deltoid muscle of the arm opposite to that of the second injection . The site of 
injection (right or left arm) and time of administration will be recorded on the appropriate 
eCRF.   
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           55 
CONFIDENTIAL  
 • Observe subjects in the clinic for ≥30 minutes after vaccination to monitor for any acute 
reactions.  
• Evaluate the vaccination site and assess for reactogenicity and AE/SAEs for ≥30 minutes 
after vaccination and before di scharge from clinic and record on the appropriate CRF.  
• Subjects will enter their reactogenicity information on a memory aid. Subjects will be 
provided a thermometer , ruler  and memory aid and will record daily oral temperature, 
solicited injection site and systemic reactions, any unsolicited AEs, and concomitant 
medications. Subjects will be asked to bring their memory aid with them at their next 
study visit.  
• Assess all AE/SAEs and new onset chronic medical conditions  and record them on the 
appropriate eCRF.  
 
7.4.4.  Visit 05, Day 16  (window: +2 days)  
 
• If a subject has a positive symptom screen  prior to the visit (per the MOP),  viral testing 
may be performed during this study visit  with a research -based assay    
• Obtain interim medical history, including an assessment for new medical conditions by 
interview of subjects and note any changes since the previous clinic visit or phone call.  
• Record all concomitant medications on the appropriate eCRF.  
• Obtain vital signs including oral temperature, blood pressure, an d pulse.  
• A targeted physical examination will be performed, if needed, by a study clinician 
licensed to make medical diagnoses and listed on Form FDA 1572 as the site PI or sub -
investigator, if indicated based on review of complete medical history.  
• Examine  vaccination site for local reactions and determine whether information recorded 
by subjects on the memory aid conforms to examination.  
• Collect blood for safety labs  (chemistry and hematology)  and developer assays . 
• Assess all AE /SAEs and new onset chronic medical conditions and record them on the 
appropriate eCRF.  
 
7.4.5.  Visit 0 6, Day 22  (window: +2 days) , Fourth Vaccination  
 
• If a subject has a positive symptom screen  prior to the visit (per the MOP),  viral testing 
may be performed during this s tudy visit  with a research -based assay    
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           56 
CONFIDENTIAL  
 • Review m edical history to assure continued eligibility.  
• Review eligibility criteria with subjects, and review results of all safety lab evaluations, 
before vaccination to assure continued eligibility for vaccination.  
• Review a ll concomitant medications for accuracy and completeness. Any new 
medications or vaccinations will be recorded and assessed for continued eligibility.  
• Obtain vital signs including oral temperature, blood pressure, and pulse.  
• Perform a  targeted physical examination, if indicated based on review of complete 
medical history.  
• Examine vaccination site for local reactions before  vaccination  and determine whether 
information recorded by subjects on the memory aid conforms to examination.  
• Colle ct blood for safety labs (chemistry and hematology), immunogenicity  (RFFIT 
assay) , and developer  assays before vaccination . 
• Perform a urine pregnancy test within 24 hours before fourth vaccination on all female 
subjects of childbearing potential. Results must be negative and known before fourth 
vaccination.  
• Perform pre -administration reactogenicity assessments before the fourth  vaccination to 
establish baseline. Subjects will then receive a single dose of vaccine via IM injection 
into the deltoid muscle of the arm opposite to that of the third injection . The site of 
injection (right or left arm) and time of administration will b e recorded on the appropriate 
eCRF.   
• Observe subjects in the clinic for ≥30 minutes after vaccination to monitor for any acute 
reactions.  
• Evaluate the vaccination site and assess for reactogenicity and AE/SAEs for ≥30 minutes 
after vaccination and before discharge from clinic and record on the appropriate CRF.  
• Subjects will enter their reactogenicity information on a memory aid. Subjects will be 
provided a thermometer , ruler  and memory aid and will record daily oral temperature, 
solicited injection site an d systemic reactions, any unsolicited AEs, and concomitant 
medications. Subjects will be asked to bring their memory aid with them at their next 
study visit.  
• Assess all AE/SAEs and  new onset chronic medical conditions, then record them on the 
appropriate eCRF.  
 
7.4.6.  Visit 0 7, Day 29 (window: + 14 days) 
 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           57 
CONFIDENTIAL  
 • If a subject has a positive symptom screen  prior to the visit (per the MOP),  viral testing 
may be performed during this study visit  with a research -based assay    
• Obtain interim medical history, including an assessment for new medical conditions by 
interview of subjects and note any changes since the previous clinic visit.  
• Record a ll concomitant medications on the appropriate eCRF . 
• Obtain vital signs including oral temperature, blood pressure, and pulse.  
• Perfo rm a targeted physical examination, if indicated based on review of complete 
medical history.  
• Examine vaccination site for local reactions and determine whether information recorded 
by subjects on the memory aid conforms to examination.  
• Collect b lood for immunogenicity  (RFFIT assay) , T cell  (IFN -gamma ELISPOT and 
ICS) , and developer  assays . 
• Collect blood samples for PBMCs for future use, if the subject has provided consent.  
• Assess a ll AE/SAEs and new ons et chronic medical conditions and record them  on the 
appropriate eCRF . 
 
7.4.7.  Phone Call, Visit 08, Day 50 (window +7 days)  
• Obtain interim medical history, including an assessment for new medical conditions by 
telephone interview of subjects and note any changes since the previous clinic visit.  
• Record all concomitant medications taken through 28 days after the last study vaccination 
on the appropriate eCRF.  
• Assess all AEs that occurred through 28 days after the last study vaccination and record 
them on the  appropriate eCRF.  
• Assess all SAEs and new onset chronic medical conditions and record them on the 
appropriate eCRF.  
 
7.4.8.  Visit 09, Day 91 (window ±14 days)  
• Obtain interim medical history, including an assessment for new medical conditions by 
interview of subj ects and note any changes since the previous clinic visit.  
• Obtain vital signs including oral temperature, blood pressure, and pulse.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           58 
CONFIDENTIAL  
 • Perform a  targeted physical examination, if indicated based on review of complete 
medical history.  
• Collect b lood for immunogenicity  (RFFIT assay) , MBC, and T cell  assays  (IFN -gamma 
ELISPOT) . 
• Collect blood samples for PBMCs for future use, if the subject has provided consent.  
• Assess a ll SAEs and new onset chronic medical conditions  and associated concomitant 
medicati ons and record them  on the appropriate eCRF . 
 
7.4.9.  Visit 10, Day 181 (window ±14 days)  
• Obtain interim medical history, including an assessment for new medical conditions by 
interview of subjects and note any changes since the previous clinic visit.  
• Obtain vital signs including oral temperature, blood pressure, and pulse.  
• Perform a  targeted physical examination, if indicated based on review of complete 
medical history.  
• Collect b lood for immunogenicity  (RFFIT assay) and MBC assays.  
• Collect blood samples for PBMCs for future use, if the subject has provided consent.  
• Assess a ll SAEs and new onset chronic medical conditions and associated concomitant 
medications and record  them  on the appropriate eCRF . 
 
7.5. Final Study Visit  
7.5.1.  Visit 11, Day 381 (window ±14 days)  
• Obtain interim medical history, including an assessment for new medical conditions by 
interview of subjects and note any changes since the previous clinic visit.  
• Obtain vital signs including oral temperature, blood pressure, and  pulse.  
• Perform a  targeted physical examination, if indicated based on review of complete 
medical history.  
• Collect b lood for immunogenicity  (RFFIT assay) , MBC, and T cell  assays  (IFN -gamma 
ELISPOT) . 
• Collect blood samples for PBMCs for future use, if the subject has provided consent.    
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           59 
CONFIDENTIAL  
 • Assess a ll SAEs and new onset chronic medical conditions and associated concomitant 
medications and record  them  on the appropriate eCRF . 
7.6. Early Termination Visit   
The following activities will be performed at the early termination visit for subjects who 
withdraw, or are withdrawn or terminated from this trial: 
• Obtain interim medical history, including an assessment for new medical conditions by 
interview of subjects  and note any changes since the previous clinic visit or phone call.  
• Record all concomitant medications on the appropriate e CRF  (if before  28 days after the 
last vaccination).  
• Obtain vital signs including oral temperature, blood pressure, and pulse.  
• Perform a targeted physical examination, if indicated based on review of complete 
medical history.  
• Examine vaccination site for local reactions if visit occurs ≤28 days after last injection .  
• Review memory aid if visit occurs ≤15 days after last injection .   
• Obtain labs (safety and immunogenicity) appropriate to that visit if visit occurs within 
window of a regular study visit.  
• Perform a urine pregnancy test on all female subjects of childbearing potential (if 
indicated)  
• Assess patient for AE/SAEs and new o nset chronic medical conditions and associated 
concomitant medications and record on the appropriate e CRF  (AEs only through Day 
28). 
7.7. Unscheduled Visit  
Unscheduled visits may occur at any time during this trial. Labs may be drawn at PI discretion. 
Any of t he following activities may be performed:  
• If an unscheduled visit occurs ≤14 days after any study vaccination, the subject will 
undergo a s ymptom screen prior to the visit , and if the screen is positive (per the MOP),  
viral testing may be performed during this visit with a research -based assay   
• Obtain interim medical history, including an assessment for new medical conditions by 
interview of subjects and note any changes si nce the previous clinic visit or phone call.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           60 
CONFIDENTIAL  
 • Record a ll concomitant medications on the appropriate e CRF  (if before  28 days after the 
last vaccination).  
• Obtain vital signs including oral temperature, blood pressure, and pulse.  
• A targeted physical examinatio n will be performed, if needed, by a study clinician 
licensed to make medical diagnoses and listed on Form FDA 1572 as the site PI or sub -
investigator, if indicated based on review of complete medical history.  
• Examine vaccination site for local reactions i f visit occurs ≤28 days after any vaccination , 
and if so , determine whether information recorded by subjects on the memory aid 
conforms to examination.  
• Obtain blood for safety if needed.  
• Perform a urine pregnancy test on all female subjects of childbearing  potential (if 
indicated)  
• Assess a ll AE/SAEs and new onset chronic medical conditions and associated 
concomitant medications and record them  on the appropriate e CRF . 
 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           61 
CONFIDENTIAL  
 8. STUDY PROCEDURES/EVALUATIONS    
8.1. Clinical  Evaluations  
Complete medical history will be obtained by interviewing the subjects at the first study visit. 
Subjects will be queried regarding a history of significant medical disorders of the head, eyes, 
ears, nose, throat, mouth, cardiovascular system, lungs, gastr ointestinal tract, liver, pancreas, 
kidney, urologic system, nervous system, blood, lymph nodes, endocrine system, 
musculoskeletal system, skin, and genital/reproductive tract. A history of any allergies, cancer, 
immunodeficiency, psychiatric illness, subs tance abuse, and autoimmune disease will be 
solicited. At subsequent  follow -up visits, an interim medical history will be obtained by 
interview of the subjects noting any changes since the previous clinic visit or phone call. The 
interim medical history will include an assessment for new medical conditions and symptoms.  
Concomitant medications will be collected as described in Section 6.4. 
At the first screening visit (Visit 00A), a physical examination (excluding pelvic and rectal 
examinations) will  be performed by a study clinician licensed to make medical diagnoses and 
listed  on Form FDA 1572 as the site PI or sub -investigator. For all subsequent  visits, a targeted 
physical examination may be performed by a study clinician licensed  to make medical diagnoses 
and listed on Form FDA 1572 as the site PI or sub -investigator, if ind icated based on subject’s 
interim medical history.  
Vital signs (oral temperature, pulse, and blood pressure) will be collected through Visit 1 1. Vital 
signs assessed on the screening visit will be considered as baseline. Subjects must not eat or 
drink anything hot or cold, or smoke within 10 minutes before  taking oral temperature. In the 
event of an abnormal heart rate or blood pressure due to ph ysiological variation or activity, the 
subject may rest for 10 minutes in a quiet room, and then blood pressure and/or heart rate may be 
re-measured. The repeated measurement may be used to determine eligibility per the judgement 
of the investigator.  
Heig ht and weight will be collected on the screening visit to determine BMI.  
Pre-administration reactogenicity assessments will be performed before  each vaccination. A 
subject with mild  (Grade 1)  pre-administration reactogenicity which is transient, resolving,  or 
clinically insignificant may be enrolled at the investigator’s discretion.  
Subjects will be observed in the clinic for ≥30 minutes after each vaccination. The vaccination 
site will be examined, post -administration reactogenicity assessments will be per formed, and any 
AE/SAEs will be assessed and recorded on the appropriate e CRF  before  discharge from the 
clinic.  
All subjects will complete a subject memory aid  on the day of each vaccination through Day 7 
following each  vaccination . Subject memory aids will be reviewed with the subjects for AEs 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           62 
CONFIDENTIAL  
 (solicited injection site and systemic reactions , and unsolicited AEs) . In addition, after each 
vaccination, whenever the subject is seen in the clinic or a phone call occurs (i.e. , at all 
oppo rtunities), solicited and unsolicited reactogenicity and AEs will be reviewed . 
Reactogenicity assessments will include an assessment of solicited AEs occurring from the time 
of each vaccination through Day 7  following each vaccination , which include  inject ion site 
reactions (pruritus, erythema, ecchymosis, induration/swelling, pain, and tenderness ) and  
systemic reactions (fever, chills/shivering/sweating, fatigue, malaise, myalgia and arthralgia 
(exclusive of the injection site), headache, and nausea ). 
8.2. Labo ratory Evaluations  
8.2.1.  Clinical Laboratory Evaluations  
Serum pregnancy tests will be performed by the clinical laboratory at the first screening visit 
(Visit 00A). Urine pregnancy tests will be performed by the site laboratory within 24 hours 
before  each vaccination  (Day 1 (Visit 01) , Day 8 (Visit 03), Day 15 (Visit 04)  and Day 2 2 (Visit 
06)) on all female subjects of childbearing potential. Results must be negative and known before  
randomization on Day 1 (Visit 01) and before  receipt of any vaccin ation . 
To be eligible for participation in th is trial and receipt of the first vaccine , the subject’s clinical 
screening lab evaluations must be confirmed to meet the subject inclusion criteria (see Section 
5.1). WBC s, hemoglobin, platelets , absolute neutrophil count, absolute lymphocyte count, ALT, 
AST, total bilirubin BUN, creatinine, and urine dipstick for glucose and protein will be measured  
as pa rt of screening .   
Subjects will be screened for HIV -1/2 antibody , hepatitis B surface antigen ( HBsAg ), and 
hepatitis C virus ( HCV ) antibody . If a positive result occurs, the subject will be referred for 
appropriate follow -up and results reported as required by state law. These screening tests must be 
negative for the subject to be eligible to participate.  
Clinical safety lab parameters evaluated a fter receipt of vaccine  (on Days 2, 8, 16, and Day 22)  
will include WBC s, hemoglobin, platelets , absolute neutrophil count, absolute lymphocyte count, 
ALT, AST, total bilirubin, BUN, and creatinine.  
8.2.2.  Special Assays  
Immunogenicity Assays  
8.2.2.1.  Rabies virus neutralization assay   
The RFFIT is a  serum neutralization assay performed on chamber slides . The RFFIT has a 24 -
hour incubation period for virus -serum -cell and includes a 5-fold serial dilution of the serum. 
The RFFIT reading is virus positiv e counts per microscopic field (20 fields per well) . In the 
Kansas State University ( KSU ) rabies laboratory , the RFFIT is fully validated per FDA and ICH 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           63 
CONFIDENTIAL  
 guidelines for human testing . The laboratory is  CLIA certified . The lab ’s RFFIT is approved by 
most ra bies-free areas including the EU ( https://ec.europa.eu/food/animals/pet -
movement/approved -labs_en ) and is recognized by the USDA for rabies serology testing for pet 
export . 
RFFIT assays will be performed on Days 1, 8, 15, 22, 29, 9 1, 181, and 3 81 (Visits: 1, 3, 4, 6, 7, 
9, 10, and 1 1). 
8.2.2.2.  Cell-mediated immunity assays  
IFN-gamma ELISPOT assays will be performed on Days 1, 15, 29, 91, and 3 81 (Visits: 1, 4, 7, 
9, and  11).  
ICS will be run at peak of T cell response, which is expected  on Day 15 for subj ects assigned to 
Groups A and B and on Day 29 for subjects assigned to Group C .  
MBC ELISPOT will be done at Days 1, 9 1, 181 and 3 81 (Visits 1, 9, 10 and 11). 
8.2.2.3.  Developer assays  
Blood will be collected for the vaccine developer to conduct  assays  that may include early 
vaccine responses , multi -plex protein assays , and anti -vector antibody assays . Blood (PAXgene 
tubes ) for early vaccine responses  will be collected on Days 1, 2, 8, 15, 16, 22, and 29.  Blood for 
multi -plex protein assays will be collected on  Days 1, 2, 8, 15, 16, 22 and 29 .  These assays are 
to support the design of future studies with this vaccine.   Data from these assays will not  be 
collected as part of this study.  Blood for anti -vector antibody assays will be collected on Days 1 
and 29.   Anti-vector antibody data will be collected as a exploratory endpoint.   
8.2.2.4.  Virus/ SARS -CoV -2 testing  
Subjects that have  a positive symptom screen prior to Visits 02, 03, 04, 05, 06, and 07 (per the 
MOP),  may be tested for SARS -CoV -2 using a research -based assay. Samples may be collected 
during or after visits on Days 2, 8, 15, 16, 22, and 29.  If a positive result occurs, the subject will 
be referred for appropriate follow -up and results reported as required by state law.  
8.2.3.  Specimen Preparation, Handling, and Shipping  
PBMC samples  for T cell assays will be collected on Days 1,  15, 29, 91, 181, and 381. For 
samples  scheduled to be collected during vaccination visits, samples  will be  collected before  
vaccination. Serum for antibody assays will be collected on Days 1, 8, 15, 22, 29, 9 1, 181, and 
381. Plasma from the PBMC separations will be saved as described in the M OP. 
8.2.3.1.  Instructions for Specimen Preparation, Handling, and Storage  
Instructions for specimen preparation, handling, and storage are included in the MOP.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           64 
CONFIDENTIAL  
 8.2.3.2.  Specimen Shipment  
Specimen shipment will occur at intervals during this trial following all applicable In ternational 
Air Transport Association (IATA) requirements and according to the specifics for storage 
temperature and documentation as detailed in the MOP.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           65 
CONFIDENTIAL  
 9. ASSESSMENT OF SAFETY  
9.1. Specification of Safety Parameters  
Safety will be assessed by the frequency and /or severity of:  
• Solicited injection site and systemic reactogenicity events from the time of each 
vaccination through Day 7 after each vaccination, overall and in each dose group.  
• Serious SAEs considered study vaccine -related and reported at any time after the first 
vaccination through the end of th is trial , overall and in each dose group.  
• Vaccine -related lab AEs through study Day 22 , overall and in each dose group.  
• Unsolicited vaccine -related AEs from the time of the first vaccination through  Day 28 
after the last vaccination, overall and in each dose group.  
• New onset chronic medical condition s at any time after the first vaccination and through 
the end of th is trial , overall and in each dose group.  
• Local, systemic, or lab toxicities after  any vaccination, overall and in each dose group.  
• Local reactogenicity through Day 7 after any vaccination, overall and in each dose group.  
• Any SAEs , overall and in each dose group.  
9.2. Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  
9.2.1.  Adverse Events  
ICH E6 defines an AE as any untoward medical occurrence in a patient or clinical investigation 
subject administered a study product regardless of its causal relationship to the study product 
administration . FDA defines an A E as any untoward medical occurrence associated with the use 
of a study product  in humans, whether or not considered study product -related.  
An AE can therefore be any unfavorable and unintended sign (including an abnormal lab 
finding), symptom, or disease temporally associated with use of the study  product. The 
occurrence of an AE may come to the attention of study personnel during study visits and 
interviews of a study product recipient presenting for medical care, or upon review by a study 
monitor.  
AEs, including solicited local (injection site) and systemic (subjective and quantitative) 
reactions , will be captured on the appropriate data collection form and eCRF.  Information to be 
collected for unsolicited non -serious AEs includes event des cription, date of onset, assessment of 
severity , relationship to study product , and alternate etiology  (assessed only by those with the 
training and authority to make a diagnosis  and listed on Form FDA 1572 as  an investigator), date 
of resolution , seriousn ess, and outcome.  AEs occurring during th is trial and reporting period will  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           66 
CONFIDENTIAL  
 be documented appropriately regardless of relationship  to study product . AEs will be followed 
through  resolution.  
Any medical condition that is present at the time that the subjec t is screened will be considered 
as baseline and not reported as an AE. However, if the severity of any pre -existing medical 
condition increases , it should be recorded as an AE.  
All AEs will be graded for severity and relationship to study product  (see definitions) . AEs 
characterized as intermittent require documentation of onset and duration of each episode. The 
start and stop date of each reported AE will be recorded on the appropriate data collection form 
and eCRF.  
Severity of Event:    
AEs will be assessed by the investigator using a protocol -defined grading system  (toxicity table 
included as an appendix) . For events not included in the protocol -defined grading system, the 
following guidelin es will be used to quantify severity:  
Mild (Grade 1) : Events require minimal or no treatment ; do not interfere with the subject’s daily 
activities.  
Moderate (Grade 2) : Events result in a low level of inconvenience or concern with therapeutic 
measures ; may cause some interference with functioning and daily activities.  
Severe (Grade 3) : Events interrupt the subject’s daily activities and may require systemic drug 
therapy or other treatment ; are usually incapacitating.  
Changes in the severity of an AE should be documented to allow an assessment of the duration 
of the event at each level of intensity to be performed.  
Relationship to Study Products:  
The assessment of the relationship of an AE to administration of a study product is made only by 
those with  the training and authority to make a diagnosis and listed on Form FDA 1572 as an 
investigator based on all available information at the time of the completion of the eCRF.  
Whether the AE is related or not  is not a factor in determining what is or is not r eported in this 
trial. If there is any doubt as to whether a clinical observation is an AE, the event should be 
reported.  Solicited injection site AEs reported during the reporting period will be considered 
related.  
In a clinical trial, the study product m ust always be suspect. To help assess  relatedness , the 
following guidelines are used.  
Related  – There is a reasonable possibility that the study product caused the AE; that is, there is 
evidence to suggest a causal relationship between the study product an d the AE. 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           67 
CONFIDENTIAL  
 Not Related  – There is not a reasonable possibility that the administration of the study product 
caused the AE. 
9.2.2.  Reactogenicity  
Reactogenicity events are AEs that are common and known to occur following administration of  
vaccine s. The Toxicity Table (Appendix C) will be used to grade solicited local (injection site) 
and systemic (subject ive and quantitative) reactions.  
9.2.3.  Serious Adverse Events  
Serious Adverse Event (SAE):  
An AE or suspected AE is considered “serious” if, in the view of either the investigator or 
sponsor, it results in any of the following outcomes:  
Death,  
• a life -threatening AE 
• inpatient hospitalization or prolongation of existing hospitalization,  
• a persistent or significant i ncapacity or substantial disruption of the ability to conduct 
normal life functions, or  
• a congenital anomaly/birth defect.   
Important medical events that may not result in death, be life -threatening, or require 
hospitalizations may be considered serious when, based upon appropriate medical judgment they 
may jeopardize the patient or subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition. Examples of such medical events include allergic 
bronchospas m requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in inpatient hospitalization, or the development of drug 
dependency or drug abuse.  
An AE is considered “life -threatening” if, in the view of  either the site PI or sponsor, its 
occurrence places the patient or subject at immediate risk of death. It does not include an AE, 
had it occurred in a more severe form, might have caused death.  
SAEs will be:  
• Assessed for severity and relationship to the vaccine  and alternate etiology.  
• Recorded on the appropriate SAE data collection form and eCRF.  
• Followed through resolution.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           68 
CONFIDENTIAL  
 • Reviewed and evaluated by an Independent Safety Monitor (ISM) (as deemed necessary), 
the SMC (periodic review unless related), DMID,  and IRB.  
9.2.4.  Procedures to be Followed in the Event of Abnormal Laboratory Test Values or 
Abnormal Clinical Findings    
The site PI or appropriate sub -investigator is responsible for recording all AE/SAEs that are 
observed or reported during this trial, regardless of the relationship to the vaccine . AE/SAEs or 
abnormal clinical findings will be collected, assessed, documented, reported, and followed 
appropriately.  
9.3. Reporting Procedures  
9.3.1.  Serious Adverse Events  
SAEs will be followed until resolution even if this extends beyond the study -reporting period. 
Resolution of an AE is defined as the return to pretreatment status or stabilization of the 
condition with the expectation that it will remain chronic.  
Any AE that meets a protocol -defined serious criterion will be submitted immediately 
(within 24 hours of site awareness) on an SAE form to the DMID Pharmacovigilance 
Group, at the following address:  
DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support (CROMS)  
6500  Rock Spring Dr. , Suite 650  
Bethesda, MD 20817, USA  
SAE Hot Line: 1 -800-537-9979 (US) or 1 -301-897-1709 (outside US)  
SAE FAX Number: 1 -800-275-7619 (US) or 1 -301-897-1710 (outside US)  
SAE Email Address: PVG@dmidcroms.com  
In addition to the SAE form, select SAE data fields will also be entered into Advantage EDCSM. 
Please see the MOP for details regarding this procedure.  
Other supporting documentation of the event may be requested by the DMID Pharmacovigilance 
Group and sh ould be provided as soon as possible.  
The site will send a copy of the SAE report(s) to the ISM (as deemed necessary) when they are 
provided to the DMID Pharmacovigilance Group. The DMID Medical Monitor and DMID C PM 
will be notified of the SAE by the DMID  Pharmacovigilance Group. The DMID Medical 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           69 
CONFIDENTIAL  
 Monitor will review and assess the SAE for regulatory reporting and potential impact on study 
subject safety and protocol conduct.  
At any time after completion of th is trial , if the site PI or appropriate sub -investigator becomes 
aware of an SAE that is suspected to be related to the vaccine , the site PI or appropriate sub -
investigator will report the event to the DMID Pharmacovigilance Group.  
9.3.2.  Regulatory Reporting for Studies Conducted Under DMID -Sponsored IND  
Following notification from the investigator, DMID, the Investigational New Drug (IND) 
sponsor, will report any suspected adverse reaction that is both serious and unexpected. DMID 
will report an AE as a suspected adverse reaction only if there is evidence  to suggest a causal 
relationship between the vaccine and the AE. DMID will notify FDA and all participating 
investigators (i.e., all investigators to whom the sponsor is providing vaccine under its IND(s) or 
under any PI’s IND(s)) in an IND safety report of potential serious risks from clinical trials or 
any other source, as soon as possible, but in no case later than 15 calendar days after the sponsor 
determines that the information qualifies for reporting as specified in 21 CFR Part 312.32. DMID 
will als o notify FDA of any unexpected fatal or life -threatening suspected adverse reaction as 
soon as possible, but in no case later than 7 calendar days after the sponsor’s initial receipt of the 
information. DMID will also notify FDA if the study is halted for a safety concern as soon as 
possible, but in no case later than 48 hours after the sponsor’s initial receipt of the information.  
Relevant follow up information to an IND safety report will be submitted as soon as the 
information is available. Upon request from FDA, DMID will submit to FDA any additional data 
or information that the agency deems necessary, as soon as possible, but in no case later than 15 
calendar days after receiving the request.  
All serious events designated as “not related” to vaccine (s), will be reported to the FDA at least 
annually in a summary format.  
9.3.3.  Repo rting of Pregnancy      
Pregnancies occurring in subjects will be reported via Advantage  eClinicalSM on the Pregnancy 
Report form. No further study vaccinations will be administered to pregnant subjects, but with 
the subject’s permission all study -related  blood samples will be obtained and the subject will 
continue in follow -up for safety events. Efforts  will be made to follow all pregnancies reported 
during th is trial  to pregnancy outcome pending the subject’s permission.  The suggested follow 
up schedule is detailed in the MOP.  
9.4. Type and Duration of Follow -up of Subjects after Adverse Events  
Solicited inj ection site and systemic reactogenicity events will be documented and reported from 
Day 1 through Day 8. 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           70 
CONFIDENTIAL  
 Clinical safety lab s will be collected at baseline and at Days 2 , 8, 16 and 22 . Solicited c linical 
safety lab  results  will be documented in Advantage eClinical in the Local Laboratory Results 
eCRF for these days.  Abnormal clinical safety laboratory results for solicited laboratory 
parameters ARE NOT reported as unsolicited AEs on the Adverse Event eCRF.  
Unsolicited AEs w ill be  collected and assessed through 28 days after the final vaccination. 
Unsolicited AEs are followed through resolution even if this extends beyond the reporting period 
(approximately 28 days after the last vaccination).  
SAEs and new -onset chronic medic al conditions will be collected, assessed, and followed from 
the time of the first vaccination through approximately 12 months after the last vaccination or 
until resolution or stabilization.  
Resolution of an AE/SAE is defined as the return to pretreatment  status or stabilization of the 
condition with the expectation that it will remain chronic.  
Follow -up procedures, evaluations, and outcomes will be recorded on the appropriate e CRF . 
9.5. Halting Rules    
 
This trial may be halted due to ISM, SRC, SMC, or PI review or at the discretion of DMID.  
Halting Rules for Sentinel Subjects  (safety reviews through Day 8 , which occurs 7 days after 
first study  vaccination)  
If any of the following halting rules are met by the first group of sentinel subjects, th is trial will 
not proceed with dose escalation to the second group of sentinel subjects without a DMID -
approved SMC recommendation to proceed.  
• One or more subjects experiences a study vaccine -related Grade 3  solicited systemic AE.   
• One or more subjects experiences a study vaccine -related Grade 3 unsolicited AE . 
• One or more subjects experiences a study vaccine -related Grade 2 or greater laboratory 
AE.  
• One or more subjects experience s a study vaccine -related Grade 3 solicited local in jection 
site AE .  
• One or more subjects experiences injection site ulceration, abscess, or necrosis judged to 
be related to  study vaccine.  
• One or more subjects experiences laryngospasm, bronchospasm, anaphylaxis judged to 
be related to  study vaccine within 1 day of vaccination .  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           71 
CONFIDENTIAL  
 • One or more subjects experiences an allergic reaction (e.g., generalized urticaria) judged 
to be related to study vaccine within 3 days  of vaccination . 
• Any death occurs following vaccin ation .  
• Any subject experiences a  non-fatal SAE judged to be related to study vaccine.  
 
Halting Rules for Discontinuation of an Individual Subject from Additional Vaccination  
The following assessments should be performed before an additional vaccination to determine if 
the subject remains eligible. If any of the following criteria are met , a subject will not be given 
subsequent vaccinations :  
• Allergic reaction (e.g., g eneralized urticaria ) within 3 days after vaccination   
• Anaphylaxi s, laryngospasm, or bronchospasm within 1 day after vaccination  
• An SAE  judged to be related to study vaccine  
• A Grade 3 lab AE that is considered to be related to any of the study vaccines  
• A Grade 3 unsolicited AE that is considered to be related to any of the study vaccines  
• A Grade 3 solicited injection site AE that does not resolve or decrease to a lower grade 
(the measurement of ecchymosis, erythema or induration by itself will not be used as 
halting criteria)  within 2 days.  
• A Grade 3 solicited systemic AE (except fatigue, malaise and headache) considered to be 
related to any of the study vaccines  
• A Grade 3 solicited systemic AE of fatigue, malaise or headache considered to be related 
to the study vaccines, that does not resol ve or decrease to a lower grade within 2 days.  
• Female s ubject becomes pregnant  
• Subject develops a new illness or condition that meets the Exclusion Criteria  
• Subject develops a new medical condition or medication change for which continued 
participation, in  the opinion of the investigator, would pose a risk to the subject, would 
interfere with the subject’s ability to complete th is trial , or would be likely to confound 
interpretation of the results  
• Subject is no longer willing and/or able to adhere to study restrictions outlined in the 
Inclusion and Exclusion Criteria  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           72 
CONFIDENTIAL  
 • Subject has a fever (defined as an oral temperature ≥38.0 °C) or an acute illness at the 
time of boost vaccination administration. The next study vaccination can be deferred until 
the fever or i llness resolves or only minor residual symptoms remain, that in the opinion 
of the investigator, will not interfere with the ability to assess safety parameters as 
required by the protocol, provided that the boost is given within the protocol -defined 
study  window. Permission to administer vaccination outside the protocol -defined study 
window must be obtained from DMID  Medical Officer  
• Subject has a Grade 2 or greater solicited injection site or systemic AE at the time of 
boost vaccination administration. The next study vaccination can be deferred until the AE 
resolves or decreases to a lower grade, such that in the opinion of the investigator, it will 
not interfere with the ability to assess safety parameters as required by the protocol, 
provided that the boost is given within the protocol -defined study window  
Note: In case the boost vaccination is postponed, the timing of the safety/immunogenicity visits 
post-boost will be planned relative to actual vaccination day.  
 
Halting Rules for Discontinuing Further Enrollments and Vaccinations Across th is Trial 
If one or more of the following halting rules is met, further enrollment and vaccinations will be 
withheld until the SMC reviews the safety data:  
• If any subject experiences anaphylaxis, laryn gospasm, bronchospasm within 24 hours  
after study vaccination   
• If two or more subjects experience an allergic reaction (e.g.  generalized urticaria ) within 
3 days after study vaccination  
• If any subject experiences injection site ulceration, abscess, or necrosis judged to be 
related to study vaccine  
• If any subject experiences a study vaccine -related SAE   
• If any subject experiences  any life -threatening or fatal SAE without an obvious, 
alternative explanation (such as trauma ) 
• If any subject experiences  thrombosis (arterial or venous) through study Day 50  
• If two or more subjects experience the same study vaccine -related Grade 3 laboratory 
AE. 
• If two or more subjects experience the same study vaccine -related Grade 3 unsolicited 
AE 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           73 
CONFIDENTIAL  
 • If two or more subjects e xperience the same study vaccine -related Grade 3 solicited local 
injection site AE (except measured ecchymosis, erythema and induration) that does not 
resolve or decrease to a lower grade  within 2 days  
• If two or more subjects experience the same study vacc ine-related Grade 3 solicited 
systemic AE (except fatigue, malaiase and headache) that does not resolve or decrease to 
a lower grade within 1 day  
• If two or more subjects experience the same study vaccine -related Grade 3 solicited 
systemic AE of fatigue, malaise or headache that does not resolve or decrease to a lower 
grade within 2 days    
 
9.6. Safety Oversight  
9.6.1.  Safety Review Committee (SRC)  
The SRC will be composed of:  
• PI, or designee  
• Independent Safety Monitor (ISM)  
• DMID Medical Monitor (MM) or designee;  
The SRC will be responsible for reviewing halting criteria notifications in real time.  If a halting 
rule is met, the SRC will meet for safety review and assessment to confirm the event. If any of 
the study halting criteria are co nfirmed, the SMC (section 9.6.2 ) will meet to evaluate the data 
and recommend appropriateness of further enrollments and/or vaccinations.  The SRC will 
remain blinded as to treatment assignment.  
9.6.2.  Safety Monitoring Committee (SMC)  
This clinical study will utilize an SMC, which is an independent group of experts that advises 
DMID. The primary responsibility of the SMC is to monitor subject safety. The SMC is external 
to DM ID and comprises at least three  voting members. The SMC will consist of members with 
appropriate Phase 1 study expertise to help interpret  data from this trial. Its activities will be 
delineated in a SMC charter that will describe the membership, responsib ilities, and scope and 
frequency of data reviews. The SMC will operate on a conflict -free basis independently of the 
study team. The DMID or SMC may convene ad hoc  SMC meetings according to protocol 
criteria or if  concerns arise during th is trial . 
The SMC will review the safety data at the following milestones:  
• Organizational Meeting – conducted prior to the enrollment of study participants  
 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           74 
CONFIDENTIAL  
 • Scheduled Data Review Meetings – a preplanned, scheduled data review meeting – a 
scheduled meeting will take place to review cumulative data up to day 8 after dosing of 
the sentinel subject  and recommend whether to proceed to enrollment of non -sentinel 
subjects   
 
• Ad hoc meetings – an unplanned meeting convened for a specific safety concern – the 
committee will convene to review events that meet halting rules for sentinel and non -
sentinel subjects  
  
• Final Meeting – to review cumulative safety data (6 months following database lock)  
All reviews by the SMC will be performed using blind ed data initially (open session) and if 
necessary for safety of subject unblinded data  will be reviewed in closed session . Vaccination  
data, including dose interruptions, modifications, and the associated reason(s), will be reported to 
the SMC.  
9.6.3.  Independent  Safety Monitor (ISM)  
 
An Independent Safety Monitor (ISM) will be assigned for the study site. An ISM is a physician 
with relevant expertise whose primary responsibility is to provide to DMID an independent 
safety assessment in a timely fashion. Participation is for the duration of the study and is a 
voluntary position that does not rece ive payment. The ISM must meet the requirements of the 
NIAID conflict of interest policy.  
The ISM:  
• Is in close proximity to the study site and has the authority and ability to readily access 
study participant records in real time.  
• May be a member of the p articipating institution’s staff but preferably be from a different 
organizational group within the institution.  
• Should not be in a direct supervisory relationship with the investigator.  
• Should have no direct involvement in the conduct of the study.  
The IS M will:  
• Sign a Conflict of Interest (COI) certification at the time they are asked to participate and 
provide updates to this information as needed.  
• Receive reports of SAEs from the site PI and will be notified by email when DMID is 
notified of the SAE.  
• Evaluate the SAE and report their clinical assessment to DMID, through DMID -CROMS 
SOCS in a timely manner and email the report to DMID -CROMS SOCS.  
• Communicate with the investigator at the participating site as needed.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           75 
CONFIDENTIAL  
 • Review additional safety related events  at the request of DMID.  
• Provide additional information to DMID and/or the SMC by teleconference as requested.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           76 
CONFIDENTIAL  
 10. CLINICAL MONITORING  
10.1. Site Monitoring Plan  
Site monitoring is conducted to ensure that the human subjects ’ protections, study and laboratory 
procedures, and data collection processes are of high quality and meet sponsor  requirements , 
ICH/GCP guidelines , and applicable regulations, and that this trial is conducted in accordance 
with the protocol, MOP , and appli cable sponsor SOPs . The sponsor,  DMID, or its designee will 
conduct site -monitoring visits as detailed in the clinical monitoring plan.  
Site visits will be made at standard intervals as defined by DMID , and may be made more 
frequently as directed by DMID. Monitoring visits will include, but are not limited to, review of 
regulatory files, accountability records, eCRFs, ICFs , medical and laboratory reports, and 
protocol and GCP compliance. Site monitors will have access to the site, study personnel, and all 
study documentation  according to the DMID -approved site monitoring plan. Study monitors will 
meet with the site PI to discuss any problems and actions to be taken , and will document site 
visit findings and discussions.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           77 
CONFIDENTIAL  
 11. STATISTICAL CONSIDERATIONS     
11.1. Study Hy potheses  
There are two primary objectives for this trial: to assess the safety, tolerability, and 
reactogenicity of one dose of ChAd155 -RG at 5x1010vp per dose, or one or two doses of 
ChAd155 -RG at 1x1011vp per dose ; and to compare the safety, tolerability, and reactogenicity of 
one or two doses of ChAd155 -RG with three doses of RABAVERT. A secondary goal is to 
assess serum rabies VNA levels by a standard, WHO -approved, RFFIT, as assessed by immune 
response kinetics (through 12 months after the first dose of vaccination), seroconversion rates, 
and peak GMT . Also of interest are innate T cell and B cell responses, as well as ELISA binding 
antibodies . This trial, like other Phase I trials , is exploratory rather than con firmatory,  and was 
not designed to test a formal null hypothesis . 
11.2. Sample Size Considerations  
This trial will enroll 50 subjects into four treatment arms : Group A (N=14) will receive one dose 
of ChAd155 -RG at the lower dosage (5 x 1010vp); Group B (N=14) wi ll receive one dose of 
ChAd155 -RG at the higher dosage (1 x 1011vp); Group C (N= 10) will receive two doses of 
ChAd155 -RG at the higher dosage (1x1011vp); and Group D (N= 12) will receive three doses of 
RABAVERT. Randomization and safety, tolerability, and reactogenicity monitoring will be 
conducted as described in Section 5.3.1 and Section 9.6.1  respectively.  
11.2.1 Adverse Events  
The sample size of 10 -14 subjects in each treatment arm  is small given the early stage (Phase I) 
of the product’s development ; thus, the precision of estimate s for AEs is limited. Rare AEs 
associated with dose level or number of doses are not demonstrable in a trial of this size; 
however , the probabilities of observing one or more AEs within a treatment arm  given various 
true event rates are presented in  Table 2. The minimum detectable event rates for various levels 
of power are displayed in Table 3. 
 
 
  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           78 
CONFIDENTIAL  
 Table 2: Probability of Observing an Adverse Event for Various Event Rates and Sample 
Sizes  
N "True" 
Event Rate  Probability of 
Observation (%)  N "True" 
Event Rate  Probability of 
Observation (%)  
8  0.1 %  0.8 
12 0.1%  1.2 
 0.5 %  3.9 0.5%  5.8 
 1.0 %  7.7 1.0%  11.4 
 2.0 %  14.9 2.0%  21.5 
 3.0 %  21.6 3.0%  30.6 
 4.0 %  27.9 4.0%  38.7 
 5.0 %  33.7 5.0%  46.0 
10.0 %  57.0 10.0%  71.8 
20.0 %  83.2 20.0%  93.1 
10 0.1%  1.0 
14 0.1%  1.4 
0.5%  4.9 0.5%  6.8 
1.0%  9.6 1.0%  13.1 
2.0%  18.3 2.0%  24.6 
3.0%  26.3 3.0%  34.7 
4.0%  33.5 4.0%  43.5 
5.0%  40.1 5.0%  51.2 
10.0%  65.1 10.0%  77.1 
20.0%  89.3 20.0%  95.6 
 
 
 
 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           79 
CONFIDENTIAL  
 Table 3: Minimum Detectable Event Rates for Various Levels of Power and Sample Size  
N Desired 
Power 
Level  Detectable 
Event Rate 
(%) N Desired 
Power 
Level  Detectable 
Event Rate 
(%) 
8 0.80 18.2 
12 0.80 12.6 
0.90 25.0 0.90 17.5 
0.95 31.2 0.95 22.1 
0.99 43.8 0.99 31.9 
10 0.80 14.9 
14 0.80 10.9 
0.90 20.6 0.90 15.2 
0.95 25.9 0.95 19.3 
0.99 36.9 0.99 28.0 
 
11.2.2 Immunogenicity  
This trial  was not designed to formally test any hypotheses associated with the immunogenicity 
data. The 95% confidence intervals for multiple observed seroconversion rates at various sample 
sizes were calculated assuming observed seroconversion rates of 90%, 95%, a nd 100%, as shown 
in Table 4.   
Table 4: 95% Confidence Intervals for Seroconversion Rate for Various Rates and Sample 
Sizes  
N Seroconversion 
Rate  95% CI  N Seroconversion 
Rate  95% CI  
8 90% ( 50 %,  100 %)  
12 90% ( 59 %,  100 %)  
95% ( 56 %,  100 %)  95% ( 66 %,  100 %)  
100%  ( 63 %,  100 %)  100%  ( 74 %,  100 %)  
10 90% ( 55 %,  100 %)  
14 90% ( 62 %,   99 %)  
95% ( 62 %,  100 %)  95% ( 69 %,  100 %)  
100%  ( 69 %,  100 %)  100%  ( 77 %,  100 %)  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           80 
CONFIDENTIAL  
  
11.3. Planned Interim Analyses   
For purposes of planning subsequent research and to allow internal and external presentations of 
data (e.g., national and/or international conferences and early publication of data), there will be 
one planned interim safety and immunogenicity analysis .  Results of the interim analys is will not 
be used to make any decisions concerning the conduct of this trial.  
Once at least half the  subject s complete the Day 91 visit the clinical database will be cleaned, 
monitored, and a data freeze created . Unblinded analyses of safety, reactogenicity, and available 
immunogenicity data are planned. The interim report will be prepared by the SDCC after the 
interim clinical database is frozen  and all VNA data through Day 91 for subjects  for whom data 
are available at the time of database freeze  are received.  
Investigators will remain blinded to individual subject treatment assignment, and will be 
provided only  data summaries aggregated by dose -group or blinded by -subject data.  
For the purpose of advancing from the two groups of sentinel subjects to enrollment of the 
remainder of subjects, the SMC will review safety data. The halting rules described elsewhere in  
this protocol (Section 9.5) will be utilized to pause this trial if certain criteria are met.  
11.3.1.  Interim Safety Review  
Safety data for the first set of four sentinel subjects will not be reviewed by the SMC  before 
enrollme nt of the second set of four sentinel subjects  if no pre -defined halting rule is met. Safety 
data for all 8 sentinels will be reviewed by the SMC prior to enrollment of the remaining 42 
subjects. These sentinel reviews will not involve hypothesis testing and will not be considered in 
estimating the precision of any estimates made at the conclusion of th is trial .  
The interim analysis will include all safety and immunogenicity data through Day 91  for subjects 
for whom data ar e available at the time of database freeze . The interim safety analyses will be 
specified in the Statistical Analysis Plan and may include tables summarizing demographics, 
study status, and protocol adherence information. Tables and figures will present un solicited 
adverse events by MedDRA System Organ Class (SOC) and Preferred Team (PT), severity, and 
relationship to study product. Solicited adverse events will be summarized by symptom, severity, 
and study day. Laboratory results will be summarized by para meter, severity, and study day. 
Blinded l istings of early terminations, protocol deviations, and clinical data may be included.  
Since this early analysis of the data is not intended to impact the conduct of th is trial, it has no 
impact on Type I error and adjustments are not planned.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           81 
CONFIDENTIAL  
 11.3.2.  Interim Immunogenicity Review  
The interim analys is will include all available immunogenicity (VNA -RFFIT) data through Day 
91 for the subjects for whom data are available at the time  of database freeze , respectively 
addressing secondary objective. The interim immunogenicity analyses will include summaries of 
geometric mean titers (GMTs) and their associated 95% confidence intervals (CIs) as well as 
peak GMT by treatment arm at study t imepoints outlined in Appendix  A. Titer results will also 
be displayed in reverse cumulative distribution (RCD) curves by visit and treatment arm.  No 
hypothesis tests or modeling will be included in the interim immunogenicity analysis. Since this 
early analysis of the data is not intended to impact the conduct of this trial, it has no impact on 
Type I error and adjustments are not planned.  
11.4. Final Analysi s Plan  
The primary Clinical Study Report (CSR) will summarize all safety and protocol -specified 
humoral immunogenicity results, including all primary and secondary endpoint data, collected 
through the final study visit for the last subject.   Prior to the i nterim database freeze , a formal 
Statistical Analysis Plan will be developed that specifies all planned analyses of primary and 
secondary endpoints, and indicates which analyses will be included in the interim analyses and 
primary CSR . In the following an  abbreviated version of the planned primary and secondary 
analysis is provided.  Additional exploratory humoral and cellular immunogenicity assessments 
may be summarized in one or more addenda to the main CSR.  
11.4.1 Analysis Populations  
  
 Intent to Treat  Population  
The modified intent -to-treat (mITT) population includes all subjects who received at least one 
dose of study vaccine and contributed both pre - and at least one post -study vaccination venous 
blood samples for immunogenicity testing for which val id results were reported. For analyses 
using the mITT population, subjects will be grouped based on randomized treatment arm.  
 Per Protocol Population  
The per protocol (PP) population includes all subjects in the mITT subset with the following 
exclusions:  
• Data from all available visits for subjects found to be ineligible at baseline , according to 
the inclusion and exclusion criteria at the time of the subject’s enrollment . 
• Data from subjects who have a baseline rabies VNA concentration ≥ 0.5 IU/mL (for the 
immunogenicity analyses)   
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           82 
CONFIDENTIAL  
 • Data from all visits subsequent to the following, such as:  
o Study withdrawal or treatment discontinuation,   
o Any study vaccination dose received out of window,  
o Receipt of non -study licensed live vaccine within 30 days before or after each 
study vaccination,  
o Receipt of non -study licensed inactivated vaccine within 14 days before or after 
each study vaccination,  
o Receipt of immunosuppressive therapy (e.g., corticosteroids) within 30 days 
before or after each study vaccination.  
o Receipt of chloroquine or hydroxychloroquine  
• Data from any visit that occurs out of window, as defined in Appendix A “Window for 
each stud y visit”.  
 Safety Population  
The Safety Population will consist of all subjects who have received at least one dose of vaccine 
and for whom any data on safety are available. Subjects will be classified according to the 
vaccine and dosage received. The prim ary safety analysis will be performed using this 
population.  
11.4.2 Baseline Characteristics  
Baseline characteristics overall and within each treatment arm  will be summarized. For both 
continuous and categorical variables, appropriate summary statistics wi ll be applied. For 
continuous variables, descriptive statistics will include the number of non -missing values, mean, 
standard deviation, median, minimum, and maximum. For categorical variables, descriptive 
statistics will include counts and percentages per  category.  
11.4.3 Safety Analysis Plan  
Safety evaluations will be based on the incidence, severity and type of AEs. Clinically significant 
physical examination findings and vital signs will be documented on an AE case report form. 
Safety variables will be tabulated and presented for all subjects in the safety population, overall 
and for each treatment arm .   
AEs will be coded by the Medical Dictionary for Regulatory Activities (MedDRA) for preferred 
term and SOC . The number and percentage of subjects experi encing each specific AE, along 
with 95% confidence intervals, will be tabulated by severity and by relatedness to vaccine . The 
number of AEs and SAEs will be reported by a detailed listing showing the type, MedDRA 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           83 
CONFIDENTIAL  
 coding, relevant dates (administration and AE), severity, relatedness, and outcome for each 
event.  
Solicited local injection site and systemic reactogenicity will be summarized by severity for each 
day post vaccination (Day s 1-7 post each vaccination ) and as the maximum severity over all 7 
days. Additionally, solicited AEs will be analyzed by taking the most severe response over the 
follow -up period, dichotomizing i nto a binary variable (none versus mild, moderate, or severe) 
and using exact confidence intervals to summarize the proportion of subjects reporting each 
symptom, any injection site symptom, and any systemic symptom. Solicited AEs will be 
summarized separa tely for each vaccination , and over all vaccinations  by treatment arm . 
Laboratory toxicities will be analyzed by taking the most severe response over the follow -up 
period, dichotomizing into a binary variable (none versus mild, moderate, or severe) and usi ng 
exact confidence intervals to summarize the event and toxicity rates. Tabular and graphical 
summaries of events will be presented for each laboratory parameter, by type, severity (none, 
mild, moderate, severe), and time point post -administration.  
Labora tory and vital sign data will also be presented as change from baseline. Variable 
transformations will be applied as appropriate. Shift tables may be produced for select laboratory 
parameters.  
11.4.4 Immunology Analysis Plan  
Seroconversion is defined as a chieving a serum antibody level post -vaccination that is greater 
than 0.5 IU/mL, the pre -defined protective titer in the KSU RFFIT assay.  
Seroconversion rates and GMT for rabies VNA titers will be calculated for each antibody 
timepoint by treatment arm, an d will be summarized graphically.   
Seroconversion rates and GMT will be presented with their corresponding 95% confidence 
interval estimates at each time point and overall peak GMT, and the pair -wise differences 
between seroconversion rates by treatment a rm will be summarized by study day along with 95% 
confidence intervals. In an exploratory analysis, the relationship between the proportion of 
seroconverters and vaccine type, dosage, and number of doses  may be examined using mixed -
effects logistic regres sion models for longitudinal data.  
All GMT calculations will use log10 transformed data, and the anti -log of the resulting point 
estimates will be reported for means and 95% confidence intervals. The relationship between the 
log-transformed titer values, vaccine type, and dosage, and dose number will be modeled using 
longitudinal regression methods in an exploratory analysis. The distribution of antibody titers 
will also be graphically summarized using the reverse cumulative frequency distribution of titer s 
by study day, and treatment arm.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           84 
CONFIDENTIAL  
 Cellular immunology assays  and anti -vector antibody responses  are exploratory endpoints and 
will be analyzed as described in the Statistical Analysis Plan (SAP).  
11.4.5 Missing Values and Outliers  
Missing safety and/or immunogenicity data will not be imputed. No search for outliers will be 
performed. However, the logarithmic transform will be used as appropriate to improve the 
distributional properties of the data and reduce the impact of potential outliers.  
 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           85 
CONFIDENTIAL  
 12. SOUR CE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  
The site will maintain appropriate medical and research records in compliance with ICH E6, 
Section 4.9 and regulatory and institutional requirements for the protection of subject 
confidentiality. The site will permit authorized representatives of DMID, its des ignees, and 
appropriate regulatory agencies to examine (and when required by applicable law, to copy) 
clinical records for the purposes of quality assurance reviews, audits, and evaluation of the study 
safety and progress. These representatives will be per mitted access to all source data  and source 
documents , which include, but are not limited to, hospital records, clinical and office charts, 
laboratory notes, memoranda, subjects’ memory aid s or evaluation checklists, pharmacy 
dispensing records, recorded d ata from automated instruments, copies or transcriptions certified 
after verification as being accurate and complete, microfiches, photographic negatives, microfilm 
or magnetic media, x -rays, and subject files and records kept at the pharmac ies, laboratori es, and 
medico -technical departments involved in th is trial. 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           86 
CONFIDENTIAL  
 13. QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written DMID -approved site quality management plan, the site and its 
subcontractors are  responsible for conducting routine QA and quality control  (QC) activities to 
internally monitor study progress and protocol compliance. The site PI will provide direct access 
to the study sites, source data/data collection forms, and reports for monitoring and auditing by 
the sponsor, and inspection by local and  regulatory authorities. The site PI will ensure all study 
personnel are appropriately trained and applicable documentations are maintained at the site. 
The SDCC will implement QC procedures beginning with the data entry system , and generate 
data QC checks that will be run on the database. Any missing data or data anomalies will be 
communicated to the site  for clarification and resolution.  
DMID -designated clinical monitors will ver ify that th is trial is conducted , and data are 
generated, documented (recorded), and reported in compliance with the protocol, ICH/GCP 
guidelines, and applicable regulatory requirements. Clinical monitoring reports will be submitted 
to DMID.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           87 
CONFIDENTIAL  
 14. ETHICS/PROTECT ION OF HUMAN SUBJECTS  
 
14.1. Ethical Standard  
The site PI will ensure that this trial is conducted in full conformity with principles of the 
Belmont Report: Ethical Principles and Guidelines for the Protection  of Human Subjects of 
Research ( National Commission for the Protection of Human Subjects of Biome dical and 
Behavioral Research [April 18, 1979 ]) and codified in 45 CFR 46, 21 CFR 50 , and 21 CFR 56, 
as applicable. The site PI will also ensur e conformity with ICH E6 GCP, and applicabl e federal 
regulations, guidance , and guidelines for G CP and Clinical Trials with humans.  
14.2. Institutional Review Board  
The site PI will obtain IRB approval for this protocol to be conducted at the site, and send 
supporting documentation to DMID before initiating recruitmen t of subjects. The investigator 
will submit applicable information to the IRB/IEC on which it relies for the review, to conduct 
the review in accordance with 45 CFR 46, ICH E6 GCP, and as applicable,  21 CFR 56 , 21 CFR 
50, and other federal, state, and local regulations. The IRB/IEC will be registered with the Office 
of Human Research Protection  (OHRP ) as applicable to the research. DMID  will receive the 
documentation that verifies IRB/IEC -approval for this protocol, associated ICFs , and upon 
request any recruitment material and handouts or surveys intended for the subjects, before  the 
recruitment and enrollment of subjects.  
Any amendments to the protocol or consent materials will be approved by the IRB/IEC before 
they are implem ented. IRB/IEC review and approval will occur at least annually throughout the 
enrollment and follow -up of subjects, and may cease if annual review is no longer required by 
applicable regulations. The investigator will notify the IRB/IEC of deviations from  the protocol 
and reportable SAEs, as applicable to the IRB/IEC policy.  
Each institution engaged in this research will hold a current Federalwide Assurance (FWA) 
issued by OHRP for federally -funded research.  
14.3. Informed Consent Process  
Informed consent is a process that is initiated before  an individual agree s to participate in a trial 
and continu es throughout the individual’s trial participation. Before any study procedures are 
performed, informed consent will be obtained and documented . Subjects will receive a concise 
and focused presentation of key information about th is trial, verbally and with a written ICF. The 
explanation will be organized, and presented in lay terminology and language that facilitates 
understanding of why one migh t or might not want to participate.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           88 
CONFIDENTIAL  
 An investigator or designee will describe the protocol to potential subjects face -to-face. The key 
information about the purpose of th is trial , the procedures and experimental aspects of th is trial , 
risks and discomforts , any expected benefits to the subject, and alternative treatment will be 
presented first to the subject.  
Subjects will also receive an explanation that th is trial involves research, and a detailed summary 
of the proposed study procedures and study interve ntions/products. This will include aspects of 
this trial that are experimental, the probability for random assignment to dose groups, any 
expected benefits, all possible risks (including a statement that the particular vaccine or 
procedure may involve risks to the subject or to the embryo or fetus, if the subject is or may 
become pregnant, that are currently unforeseeable), the expected duration of the subject’s 
participation in th is trial, alternative procedures that may be available , and the p otential benefits 
and risks of these available alternative procedures.  
Subjects will be informed that they will be notified in a timely manner if information becomes 
available that may be relevant to their willingness to continue participation in th is trial. Subjects 
will receive an explanation as to whether any compensation and any medical treatments are 
available if injury occurs, and, if so, what they consist of, or where further information may be 
obtained. Subjects will be informed of the anticipated f inancial expenses, if any, to the m for 
participating in th is trial, as well as any anticipated prorated payments, if any, to the m for 
participating in th is trial. They will be informed of whom to contact (e.g., the investigator) for 
answers to any question s relating to the research project.  
Information will also include the foreseeable circumstances and/or reasons under which the 
subject’s participation in th is trial may be terminated. The subjects will be informed that 
participation is voluntary and that t hey are free to withdraw from th is trial  for any reason at any 
time without penalty or loss of benefits to which subject s are otherwise entitled.   
The extent of the confidentiality of the subjects’ records will be defined, and subjects will be 
informed th at applicable data protection legislation will be followed. Subjects will be informed 
that the monitor(s), auditors(s), IRB, NIAID, and regulatory authority(ies) will be granted direct 
access to the subject’s original medical records for verification of cl inical trial procedures and/or 
data without violating the confidentiality of the subject, to the extent permitted by applicable 
laws and regulations, and that, by signing a written ICF, the subject is authorizing such access.  
Subjects will be informed tha t records identifying the subject will be kept confidential, and, to 
the extent permitted by applicable laws and/or regulations, will not be made publicly available 
and, if the results of th is trial are published, the subject’s identity will remain confide ntial. 
Subjects will be informed whether confidential information collected from this research and/or 
specimens will be used for additional research, even if identifiers are removed.    
Subjects will be allowed sufficient time to consider participation in this trial, and to have the 
opportunity to discuss it with their family, friends , or legally authorized representative, or think 
about it before  agreeing to participate.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           89 
CONFIDENTIAL  
 Subjects will be asked to read and review the IRB-approved ICF. Subjects must sign the ICF 
before  starting any study procedures being done specifically for this trial.  
Once signed, a copy of the ICF will be given to subjects for their records. Subjects may 
withdraw consent at any time during  this trial. The rights and welfare of subjects will be 
protected by emphasizing to them that the quality of their medical care wil l not be adversely 
affected if they decline to participate in this trial. 
Study personnel may employ recruitment efforts before  obtaining study consent if a patient -
specific screening consent is on record or if the IRB has agreed that chart review is allow ed 
without a fully executed screening consent. In cases where there is not a patient -specific 
screening consent on record, site clinical staff may pre -screen via chart review and refer potential 
subjects to the research staff. Research staff would obtain w ritten consent per the standard 
informed consent process before conducting protocol -specific screening activities.  
New information will be communicated by the site PI to subjects who consent to participate in 
this trial in accordance with IRB requirements.  The ICF will be updated and subjects will be re -
consented per IRB requirements, if necessary. Subjects will be given a copy of all ICFs  that they 
sign.  
14.4. Exclusion of Women, Minorities, and Children (Special Populations)  
This trial will include  all healthy adults who meet the inclusion/exclusion criteria, regardless of 
religion, sex, or ethnic background. Only subjects , aged  18 to 4 9 years inclusive, will be 
included. Children will be  excluded from this first -in-humans trial for safety reasons. Special 
populations, e.g ., non -English speakers, illiterate or non -writing individuals , and vulnerable 
populations , for which no benefit of trial participation has been identified,  will not be enrolled in 
this trial. 
14.5. Subject Confidentiality  
Subject confide ntiality is strictly held in trust by the participating investigators, their staff, and 
the sponsor(s) and their agents. This confidentiality includes documentation, investigation data, 
subject clinical information, and all other information generated duri ng participation in th is trial . 
No information concerning th is trial or the data generated from it will be released to any 
unauthorized third party without prior written approval of DMID  and the subject. Subject 
confidentiality will be maintained when study results are published or discussed in conferences. 
Study monitor s or other authorized representa tives of the sponsor or governmental regulatory 
agencies may inspect all documents and records required to be maintained by the investigator, 
including but not limited to, medical records (office, clinic, or hospital) and pharmacy records 
for the subjects in this trial. The site will permit access to such records.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           90 
CONFIDENTIAL  
 All records will be kept locked and all computer entry and networking programs will be carried 
out with coded numbers only and with password protected systems. All non -clinical specimens, 
evaluati on forms, reports, and other records that leave the site will be identified only by a coded 
number.  
 
Specimens provided to research labs for the assays and to GlaxoSmithKline Vaccines for testing 
with developer assays are barcoded with no subject identifie rs. A copy of the final dataset from 
this study will be provided to the pharmaceutical partner, GlaxoSmithKline Vaccines, which has 
a Federal Wide Assurance  with the Office of Human Research Protections (OHRP, HHS) to 
maintain the confidentiality of indivi dual patients.  The final dataset contains subject level data 
linked to a coded  subject identifier and not subject ID number.  
14.6. Study Discontinuation  
If this trial  is prematurely terminated by the sponsor, any regulatory authority, or the investigator 
for any reason, the investigator will promptly inform subjects and assure appropriate therapy or 
follow -up for the subjects, as necessary. The investigator will provide a detailed written 
explanation of the termination to the IRB/IEC. If any subject’s confident ial information will 
continue to be collected for this trial, the IRB/IEC will approve a n ICF  with the study 
procedures, any risks and discomforts, and applicable elements, and the investigator or designee 
will re -consent the subjects as approved by the IRB/IEC.  
14.7. Costs, Subject Compensation, and Research Related Injuries  
There is no cost to subject s for the research tests, procedures, and vaccines  while taking part in 
this trial.  Procedures and treatment for clinical care may be billed to the subject, subject’s 
insurance , or third party. Subjects may be compensated for their participation in this tr ial. 
Compensation will be in accordance with the local IRB’s policies and procedures, and subject to 
IRB approval.  
If it is determined by the site PI that an injury occurred to a subject as a direct result of the tests 
or treatments that are done for this trial, then referrals to appropriate health care facilities will be 
provided to the subject. Study personnel will try to reduce, control, and treat any complications 
from this trial. Immediate medical treatment may be provided by the site. No financial 
compensation will be provided to the subject by the NIAID, NIH to the subject . However, the 
manufacturers of the vaccines will cover research -related injury.  
14.8. Future Use of Stored Specimens  and Data  
At enrollment, s ubjects will be asked for permission to obtain blood samples for PBMC 
collection specifically for future use to perform the immunologic assays in line with the 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           91 
CONFIDENTIAL  
 exploratory objectives.  Any remaining blood samples may also be  used in future research 
studies, such as examining additional immunologi cal assessments or testing for antibodies 
against other viruses or bacteria. These residual samples will be stored indefinitely at a central 
clinical storage facility and may be shared with investigators at the site or other institutions.  
It is anticipated  that residual serum and PBMCs  will be available specifically for other future 
research, including but not limited to non -traditional immune assay development, assessing 
innate immune factors and the ability of vaccine -induced antibodies to cross -react wit h other 
rabies viruses. These future use clinical samples will be stored indefinitely at a central clinical 
storage facility.  
Residual clinical samples will be available upon the completion of th is trial ; however, future use 
clinical samples may be request ed from DMID and shipped from DMID C MS at any time.  
The samples will not be sold or used directly for production of any commercial product. No 
human genetic tests will be performed on the samples. Each sample will be encoded (labeled) 
only with a barcode a nd a unique tracking number to protect subject confidentiality.  
There are no benefits to subjects in the collection, storage and subsequent use of their specimens 
for future research. Reports about future research done with subjects’ samples will not be ke pt in 
their health records.  
Subjects may be given the option to decide if they want their samples to be used for future 
research or have their samples destroyed at the end of this trial. The subject’s decision can be 
changed at any time by notifying the st udy doctors or nurses in writing. However, if the subject 
originally consents to future use and subsequently changes his/her decision, any data from a 
previously collected sample may still be used for this research.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           92 
CONFIDENTIAL  
 15. DATA HANDLING AND RECORD KEEPING  
The inv estigator is responsible to ensure the accuracy, completeness, legibility, and timeliness of 
the data reported.  
Data collection forms will be derived from the eCRF and provided by the SDCC to record and 
maintain data for each subject enrolled in this tria l. 
 All source documents should be completed in a neat, legible manner to ensure accurate 
interpretation of data. Black or blue permanent  ink is required to ensure clarity of reproduced 
copies.  When making changes or corrections, cross out the original entry with a single line, and 
initial and date the change. DO NOT ERASE, OVERWRITE, OR USE CORRECTION FLUID 
OR TAPE ON THE ORIGINAL.  
Copies  of the eCRF will be provided for use as source data collection forms  and maintained for 
recording data for each subject enrolled in th is trial . Data reported in the eCRF derived from 
source data collection forms  should be consistent or the discrepancies s hould be explained.  
The sponsor and/or its designee will provide guidance to the site PI and other study personnel on 
making corrections to the data collection forms and eCRF.  
15.1. Data Management Responsibilities  
 
All data collection forms and laboratory repor ts must be reviewed by the clinical team and data 
entry personnel, who will ensure that they are accurate and complete. AEs must be recorded on 
the appropriate data collection form, assessed for severity and relationship, and reviewed by the 
site principal  investigator or appropriate sub -investigator.  
Data collection is the responsibility of the study personnel at the participating clinical study site 
under the supervision of the site PI. During th is trial , the site PI will maintain complete and 
accurate documentation for th is trial . 
The SDCC  for this trial will be responsible for data management, quality review, analysis, and 
reporting of the study data.  
15.2. Data Capture Methods  
Clinical (including, but not limited to, AE/SAEs,  concomitant medications, medical history, 
physical assessments, and clinical lab values ) and reactogenicity will be collected on data 
collection forms by study personnel then entered into eCRFs via a 21 CFR Part 11-compliant 
internet data entry system  provided by the SDCC . The data system includes password protection 
and internal quality checks, such as automatic range checks, to identify data that appear 
inconsistent, incomplete, or inaccurate.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           93 
CONFIDENTIAL  
 15.3. Types of Data  
Data for this trial will include clinical, safety, and outcome measures (e.g., clinical lab values, 
reactogenicity, and immunogenicity data).  
15.4. Timing/Reports  
The SDCC will produce one interim statistical report, and one final clinical study report (CSR). 
A final report will be prepared fol lowing the availability of all the clinical, safety, reactogenicity, 
and immunogenicity data.  Timing and contents of the interim report is described in Section 11.3 
of this protocol. Additional i nterim statistical reports may be generated as deemed necessary and 
appropriate by DMID.  Safety and immunogenicity summary reports may be generated for the 
SMC.  
After full analysis and final reporting is complete, and upon request and DMID approval, the 
SDCC will provide the VTEU site and subcontract site with a summary of results by treatment 
group and/or subject treatment assignments.  In this regard, the VTEU s ite and subcontract site 
requesting such information to share with study subjects must do so in compliance with their 
respective IRB guidelines.   
15.5. Study Records Retention  
Study documents will be retained for a t least  2 years after the last approval of a ma rketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of 
clinical development of the vaccine . These documents will be re tained for a longer period, 
however, if required by local regulations. No records will be destroyed without the written 
consent of the sponsor. It is the responsibility of the sponsor to inform the investigator when 
these documents no longer need to be ret ained.  
15.6. Protocol Deviations  
A protocol deviation is any noncompliance with the protocol, GCP, or MOP requirements. The 
noncompliance may be either on the part of the subject, the site PI, or the site personnel. As a 
result of deviations, corrective actions will be developed by the site and implemented promptly.  
These practices are consistent with ICH E6:  
4.5 Compliance with Protocol, Sections 4.5.1, 4.5.2, and 4.5.3  
5.1 Quality Assurance and Quality Control, Section 5.1.1  
5.20 Noncompliance, Sections 5.20.1,  and 5.20.2.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           94 
CONFIDENTIAL  
 It is the responsibility of the site PI and personnel to use continuous vigilance to identify and 
report deviations within 5 working days of identification of the protocol deviation, or within 5 
working days of the scheduled protocol -required activity. All deviations will be promptly 
reported to DMID per the SDCC protocol deviation reporting procedures . 
All protocol deviations, as defined above, will be addressed in study subject data collection 
forms. A completed copy of the DMID Protocol Deviation Form will be maintained in the 
Regulatory File, as well as in the subject's chart. Protocol deviations will be sent to the local 
IRB/IEC per their guidelin es. The site PI and personnel are responsible for knowing and 
adhering to their IRB requirements.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           95 
CONFIDENTIAL  
 16. PUBLICATION POLICY  
All investigators funded by the NIH must submit or have submitted for them to the National 
Library of Medicine’s PubMed Central (http://www.ncbi.nlm.nih.gov/pmc/) an electronic 
version of their final, peer -reviewed manuscripts upon acceptance for publication, to be made 
publicly available no later than 12 months after the official date of publication. The NIH Public 
Access Policy e nsures the public has access to the published results of NIH -funded research. It 
requires investigators to submit final peer -reviewed journal manuscripts that arise from NIH 
funds to the digital archive PubMed Central upon acceptance for publication. Furth er, the policy 
stipulates that these papers must be accessible to the public on PubMed Central no later than 12 
months after publication.  
Refer to:  
NIH Public Access Policy, http://publicaccess.nih.gov/  
NIH Office of Extramural Research (OER) Grants and Fu nding, 
http://grants.nih.gov/grants/oer.htm  
As of January 2018, all clinical trials supported by the NIH must be registered on 
ClinicalTrials.gov, no later than 21 days after the enrollment of the first subject. Results of all 
clinical trials supported by the NIH, generally, need to be submitted no later than 12 months 
following the primary completion date. A delay of up to 2 years is available for trials that meet 
certain criteria and have applied for certification of delayed posting.  
As part of the result  posting  a copy of this protocol (and its amendments) and a copy of the S AP 
will be posted on ClincialTrials.gov.  
For this trial  the responsible party is DMID , which will register th is trial and post results.   
DMID  does not plan to request certification of delayed posting.  
Refer to:   
Public Law 110 -85, Section 801, Clinical Trial Databases  
42 CFR  Part 11 
NIH NOT -OD-16-149 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           96 
CONFIDENTIAL  
 17. LITERATURE REFERENCES     
 
1. World Health Organization. Rabies - Epidemiology and burden of disease, Geneva, 
Switzerland,2017 [cited 2017 October 10]. Available from: 
http://www.who.int/rabies/epidemiology/en/ . 
2. Knobel DL, Cleaveland S, Coleman PG, Fevre EM, Meltzer MI, Miranda ME, Shaw A, 
Zinsstag J, Meslin FX. Re -evaluating the burden of rabies in Africa and Asia. Bull World Health 
Organ. 2005;83(5):360 -8. doi: /S0042 -96862005000500012. PubMed PMID: 15976877; 
PMCID: PMC2626230.  
3. Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lu mlertdacha B, Guerra M, 
Meltzer MI, Dhankhar P, Vaidya SA, Jenkins SR, Sun B, Hull HF, Advisory Committee on 
Immunization Practices Centers for Disease C, Prevention. Human rabies prevention --United 
States, 2008: recommendations of the Advisory Committee o n Immunization Practices. MMWR 
Recomm Rep. 2008;57(RR -3):1-28. PubMed PMID: 18496505.  
4. Centers for Disease C, Prevention. Use of a reduced (4 -dose) vaccine schedule for 
postexposure prophylaxis to prevent human rabies -recommendations of the Advisory Comm ittee 
on Immunization Practice. Ann Emerg Med. 2010;56(1):64 -7. PubMed PMID: 20648715.  
5. Moran GJ, Talan DA, Mower W, Newdow M, Ong S, Nakase JY, Pinner RW, Childs JE. 
Appropriateness of rabies postexposure prophylaxis treatment for animal exposures. Emer gency 
ID Net Study Group. JAMA. 2000;284(8):1001 -7. PubMed PMID: 10944646.  
6. National Association of State Public Health V, Compendium of Animal Rabies P, 
Control C, Brown CM, Slavinski S, Ettestad P, Sidwa TJ, Sorhage FE. Compendium of Animal 
Rabies Prev ention and Control, 2016. J Am Vet Med Assoc. 2016;248(5):505 -17. doi: 
10.2460/javma.248.5.505. PubMed PMID: 26885593.  
7. Capone S, D'Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, Folgori A. 
Development of chimpanzee adenoviruses as vaccine vecto rs: challenges and successes 
emerging from clinical trials. Expert Rev Vaccines. 2013;12(4):379 -93. doi: 10.1586/erv.13.15. 
PubMed PMID: 23560919.  
8. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, 
Grazioli F, Esposito ML, Ambrosio M, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka 
A, O'Hara GA, Ewer KJ, Anagnostou N, Bliss C, Hill AV, Traboni C, Klenerman P, Cortese R, 
Nicosia A. Vaccine vectors derived from a large collection of simian adenoviruses induce potent 
cellular immunity across multiple species. Sci Transl Med. 2012;4(115):115ra2. doi: 
10.1126/scitranslmed.3002925. PubMed PMID: 22218691; PMCID: PMC3627206.  
9. De Santis O, Audran R, Pothin E, Warpelin -Decrausaz L, Vallotton L, Wuerzner G, 
Cochet C, Estoppey D, Steiner -Monard V, Lonchampt S, Thierry AC, Mayor C, Bailer RT, 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           97 
CONFIDENTIAL  
 Mbaya OT, Zhou Y, Ploquin A, Sullivan NJ, Graham BS, Roman F, De Ryck I, Ballou WR, 
Kieny MP, Moorthy V, Spertini F, Genton B. Safety and immunogenicity of a chimpanzee 
adenovirus -vectored E bola vaccine in healthy adults: a randomised, double -blind, placebo -
controlled, dose -finding, phase 1/2a study. Lancet Infect Dis. 2016;16(3):311 -20. doi: 
10.1016/S1473 -3099(15)00486 -7. PubMed PMID: 26725450.  
10. Ewer K, Rampling T, Venkatraman N, Bowyer G , Wright D, Lambe T, Imoukhuede EB, 
Payne R, Fehling SK, Strecker T, Biedenkopf N, Krahling V, Tully CM, Edwards NJ, Bentley 
EM, Samuel D, Labbe G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts 
R, Hartnell F, Bliss C, Sierra -Davidson  K, Powlson J, Berrie E, Tedder R, Roman F, De Ryck I, 
Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, 
Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, 
Levine MM, Volkmann A, Chaplin P,  Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, 
Hill AV. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J 
Med. 2016;374(17):1635 -46. doi: 10.1056/NEJMoa1411627. PubMed PMID: 25629663.  
11. Tapia MD, Sow SO, Lyke KE, Haida ra FC, Diallo F, Doumbia M, Traore A, Coulibaly 
F, Kodio M, Onwuchekwa U, Sztein MB, Wahid R, Campbell JD, Kieny MP, Moorthy V, 
Imoukhuede EB, Rampling T, Roman F, De Ryck I, Bellamy AR, Dally L, Mbaya OT, Ploquin 
A, Zhou Y, Stanley DA, Bailer R, Koup RA, Roederer M, Ledgerwood J, Hill AVS, Ballou WR, 
Sullivan N, Graham B, Levine MM. Use of ChAd3 -EBO -Z Ebola virus vaccine in Malian and 
US adults, and boosting of Malian adults with MVA -BN-Filo: a phase 1, single -blind, 
randomised trial, a phase 1b, open -label and double -blind, dose -escalation trial, and a nested, 
randomised, double -blind, placebo -controlled trial. Lancet Infect Dis. 2016;16(1):31 -42. doi: 
10.1016/S1473 -3099(15)00362 -X. PubMed PMID: 26546548; PMCID: PMC4700389.  
12. Ledgerwood JE, DeZure AD, Stanley DA, Coates EE, Novik L, Enama ME, Berkowitz 
NM, Hu Z, Joshi G, Ploquin A, Sitar S, Gordon IJ, Plummer SA, Holman LA, Hendel CS, 
Yamshchikov G, Roman F, Nicosia A, Colloca S, Cortese R, Bailer RT, Schwartz RM, Roederer 
M, Mascola JR, Koup RA, Sulliv an NJ, Graham BS, Team VRCS. Chimpanzee Adenovirus 
Vector Ebola Vaccine. N Engl J Med. 2017;376(10):928 -38. doi: 10.1056/NEJMoa1410863. 
PubMed PMID: 25426834.  
13. Ewer KJ, Sierra -Davidson K, Salman AM, Illingworth JJ, Draper SJ, Biswas S, Hill AV. 
Progress  with viral vectored malaria vaccines: A multi -stage approach involving "unnatural 
immunity". Vaccine. 2015;33(52):7444 -51. doi: 10.1016/j.vaccine.2015.09.094. PubMed PMID: 
26476366; PMCID: PMC4687526.  
14. Barnes E, Folgori A, Capone S, Swadling L, Aston S , Kurioka A, Meyer J, Huddart R, 
Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O'Hara G, Willberg C, 
Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, 
Nicosia A, Cortese R, Klenerman P. Novel aden ovirus -based vaccines induce broad and 
sustained T cell responses to HCV in man. Sci Transl Med. 2012;4(115):115ra1. doi: 
10.1126/scitranslmed.3003155. PubMed PMID: 22218690; PMCID: PMC3627207.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           98 
CONFIDENTIAL  
 15. Green CA, Scarselli E, Sande CJ, Thompson AJ, de Lara CM, Taylor KS, Haworth K, 
Del Sorbo M, Angus B, Siani L, Di Marco S, Traboni C, Folgori A, Colloca S, Capone S, Vitelli 
A, Cortese R, Klenerman P, Nicosia A, Pollard AJ. Chimpanzee adenovirus - and MVA -vectored 
respiratory syncytial virus vaccine is safe and im munogenic in adults. Sci Transl Med. 
2015;7(300):300ra126. doi: 10.1126/scitranslmed.aac5745. PubMed PMID: 26268313; PMCID: 
PMC4669850.  
16. Yarosh OK, Wandeler AI, Graham FL, Campbell JB, Prevec L. Human adenovirus type 5 
vectors expressing rabies glycopro tein. Vaccine. 1996;14(13):1257 -64. PubMed PMID: 
8961515.  
17. Canadian Food Inspection Agency. Rabies Vaccine, Live Adenovirus Vector (AdRG1.3 
baits), Trade Name: ONRAB – Environmental Assessment Canada2012 [cited 2017 October 11]. 
Available from: http://w ww.inspection.gc.ca/animals/veterinary -biologics/licensed -
products/environmental -assessments/rabies -vaccine -onrab/eng/1351609458287/1351609994816 . 
18. Fehlner -Gardiner C, Rudd R, Donovan D, Slate D, Kempf L, Badcock J. Comparing 
ONRAB(R) AND RABORAL V -RG(R ) oral rabies vaccine field performance in raccoons and 
striped skunks, New Brunswick, Canada, and Maine, USA. J Wildl Dis. 2012;48(1):157 -67. doi: 
10.7589/0090 -3558 -48.1.157. PubMed PMID: 22247384.  
19. Mainguy J, Fehlner -Gardiner C, Slate D, Rudd RJ. Oral  rabies vaccination in raccoons: 
comparison of ONRAB(R) and RABORAL V -RG(R) vaccine -bait field performance in Quebec, 
Canada and Vermont, USA. J Wildl Dis. 2013;49(1):190 -3. doi: 10.7589/2011 -11-342. PubMed 
PMID: 23307388.  
20. Slate D, Chipman RB, Algeo TP , Mills SA, Nelson KM, Croson CK, Dubovi EJ, 
Vercauteren K, Renshaw RW, Atwood T, Johnson S, Rupprecht CE. Safety and immunogenicity 
of Ontario Rabies Vaccine Bait (ONRAB) in the first us field trial in raccoons (Procyon lotor). J 
Wildl Dis. 2014;50(3):582 -95. doi: 10.7589/2013 -08-207. PubMed PMID: 24807178.  
21. Xiang ZQ, Greenberg L, Ertl HC, Rupprecht CE. Protection of non -human primates 
against rabies with an adenovirus recombinant vaccine. Virology. 2014;450 -451:243 -9. doi: 
10.1016/j.virol.2013.12.029. PubMed PMID: 24503087; PMCID: PMC4038128.  
22. Cicconi P, Jones C, Klenerman P, De Lara C, Silva Reyes L, Moris P, Michel J, Fissette 
L, Picciolato M, Gonzalez Lopez A, Dieussaert I, Snape MD, editors. First -in-human study to 
assess the safety and immunogen icity of an investigational respiratory syncytial virus (RSV) 
vaccine based on ChAd155 viral vector expressing RSV viral proteins F, N, and M2 -1 in healthy 
adults. ECCMID; 2017; Vienna, Austria.  
23. RabAvert Rabies Vaccine [package insert]. Marburg, German y: GSK Vaccines; 2015.  
24. RABIPUR Rabies Vaccine [package insert]. Marburg, Germany: Novartis Vaccines; 
2006.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           99 
CONFIDENTIAL  
 25. Dobardzic A, Izurieta H, Woo EJ, Iskander J, Shadomy S, Rupprecht C, Ball R, Braun 
MM. Safety review of the purified chick embryo cell rabies  vaccine: Data from the Vaccine 
Adverse Event Reporting System (VAERS), 1997 -2005. Vaccine. 2007;25(21):4244 -51. doi: 
10.1016/j.vaccine.2007.02.075. PubMed PMID: 17382435.  
26. Pappaioanou M, Fishbein DB, Dreesen DW, Schwartz IK, Campbell GH, Sumner JW, 
Patchen LC, Brown WJ. Antibody response to preexposure human diploid -cell rabies vaccine 
given concurrently with chloroquine. N Engl J Med. 1986;314(5):280 -4. doi: 
10.1056/NEJM198601303140504. PubMed PMID: 3510393.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           100 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017  18. SUPPLEMENTS /APPENDICES  
 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial
 19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           101 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017  APPENDIX  A. SCHEDULE OF STUDY PROCEDURES AND 
EVALUATIONS    
 (see next page)   
  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial  19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           102 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017  Study Visit  1st Screen 
(D-28 to -1) 2nd Screen  
(D -28 to -1) V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 Early 
termination  Unscheduled  
Study Day post Vaccination #1 (D1)  
 
 
Enrollment 
Dose 1  
D1 
D2 +2d 
D8 +2d 
D15 +2d 
D16 +2d 
D22 +2d 
D29+14d 
D50+ 7d 
D91 ± 14d 
D181 ± 14d  
D381 ± 14d  
 
 
Study Day post Vaccination #2  
 
 
 
 
Dose 2  
D1 
D8 +2d 
D9 +2d 
D15 +2d 
D22+14d 
D43+ 7d 
D84 ± 14d 
D174 ± 14d  
D374 ± 14d  
 
 
Study Day post Vaccination #3  
 
 
 
 
 
Dose  3 D1 
D2 +2d 
D8 +2d 
D15+14d 
D36+ 7d 
D77 ± 14d 
D167 ± 14d  
D367 ± 14d  
 
 
Study Day post Vaccination #4  
 
 
 
 
 
 
 
Dose 4   
D1 
D8+14d 
D29+ 7d 
D70 ± 14d 
D160 ± 14d  
D360 ± 14d  
 
 
Signed ICF  X               
Assessment of Eligibility Criteria  X X X  X X  X        
Symptom  Screen  X X X X X X X X X X X X X   
Review of Medical History  X X X X X X X X X X X X X X (X) 
Review of Concomitant Medications  X X X X X X X X X X Xa Xa Xa X (X) 
Vaccinations (X)  
Placebo (P)  A   X 
 P P  P 
 
 
 
 
 
 
 
B   X 
 P P  P 
 
 
 
 
 
 
 
C   X 
 P X  P 
 
 
 
 
 
 
 
D   X 
 X P  X 
 
 
 
 
 
 
 
Physical Exam  Complete  X               
 Sympto m-Directed   (X) (X) (X) (X) (X) (X) (X) (X)  (X) (X) (X) (X) (X) 
 Vital Sig ns Xb Xb X X X X X X X  X X X X (X) 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial  19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           103 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017  Study Visit  1st Screen 
(D-28 to -1) 2nd Screen  
(D -28 to -1) V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 Early 
termination  Unscheduled  
Study Day post Vaccination #1 (D1)  
 
 
Enrollment 
Dose 1  
D1 
D2 +2d 
D8 +2d 
D15 +2d 
D16 +2d 
D22 +2d 
D29+14d 
D50+ 7d 
D91 ± 14d 
D181 ± 14d  
D381 ± 14d  
 
 
Study Day post Vaccination #2  
 
 
 
 
Dose 2  
D1 
D8 +2d 
D9 +2d 
D15 +2d 
D22+14d 
D43+ 7d 
D84 ± 14d 
D174 ± 14d  
D374 ± 14d  
 
 
Study Day post Vaccination #3  
 
 
 
 
 
Dose  3 D1 
D2 +2d 
D8 +2d 
D15+14d 
D36+ 7d 
D77 ± 14d 
D167 ± 14d  
D367 ± 14d  
 
 
Study Day post Vaccination #4  
 
 
 
 
 
 
 
Dose 4   
D1 
D8+14d 
D29+ 7d 
D70 ± 14d 
D160 ± 14d  
D360 ± 14d  
 
 
Assessment  of Adverse Events and New Onset 
Chronic Medical Conditions    X X X X X X X X Xc Xc Xc X X 
Examine Vaccination Site for Local Reactions (before 
vaccination on injection visits) and Review Memory 
Aid    X X X X X X     Xd Xe 
Pre-vaccine Administration Reactogenicity 
Assessment    X  X X  X        
Post-vaccination Observation  (for 30 minutes) to 
Assess Acute Reactions    X  X X  X        
Evaluation of Vaccination Site to Assess for 
Reactogenicity and AE/SAEs after 30 minutes    X  X X  X        
Subject provided with Memory Aid to Enter  
Reactogenicity Information    X  X X  X        
Pregnancy test  Serum  X               
Urine   X  X X  X        
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial  19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           104 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017  Study Visit  1st Screen 
(D-28 to -1) 2nd Screen  
(D -28 to -1) V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 Early 
termination  Unscheduled  
Study Day post Vaccination #1 (D1)  
 
 
Enrollment 
Dose 1  
D1 
D2 +2d 
D8 +2d 
D15 +2d 
D16 +2d 
D22 +2d 
D29+14d 
D50+ 7d 
D91 ± 14d 
D181 ± 14d  
D381 ± 14d  
 
 
Study Day post Vaccination #2  
 
 
 
 
Dose 2  
D1 
D8 +2d 
D9 +2d 
D15 +2d 
D22+14d 
D43+ 7d 
D84 ± 14d 
D174 ± 14d  
D374 ± 14d  
 
 
Study Day post Vaccination #3  
 
 
 
 
 
Dose  3 D1 
D2 +2d 
D8 +2d 
D15+14d 
D36+ 7d 
D77 ± 14d 
D167 ± 14d  
D367 ± 14d  
 
 
Study Day post Vaccination #4  
 
 
 
 
 
 
 
Dose 4   
D1 
D8+14d 
D29+ 7d 
D70 ± 14d 
D160 ± 14d  
D360 ± 14d  
 
 
Blood draw  X (X) X X X X X X X  X X X X (X) 
Clinical Laboratory  Chemistry  Xf (X)  X X  X X      X (X) 
Hematol ogy X (X)  X X  X X      X (X) 
Urine d ipstick  X (X)              
Research  Assay  SARS -CoV -2 test     (X) (X) (X) (X) (X) (X)       
Immunology  
(all samples on 
vaccination days will be 
collected before the 
vaccine dose is given)  Rabies nAb (RFFIT)    X  X X  X X  X X X X  
T cell (IFNγ ELISpot) 
(5x106 10x106 PBMCs)    X   X   X  X  X   
T cell (ICS) (10x106 
PBMCs)       Xg   Xg       
MBC ELISpot (5x106 
10x106 PBMCs)    X        X X X   
PBMC s for future use    X   X   X  X X X   
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial  19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           105 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017  Study Visit  1st Screen 
(D-28 to -1) 2nd Screen  
(D -28 to -1) V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 Early 
termination  Unscheduled  
Study Day post Vaccination #1 (D1)  
 
 
Enrollment 
Dose 1  
D1 
D2 +2d 
D8 +2d 
D15 +2d 
D16 +2d 
D22 +2d 
D29+14d 
D50+ 7d 
D91 ± 14d 
D181 ± 14d  
D381 ± 14d  
 
 
Study Day post Vaccination #2  
 
 
 
 
Dose 2  
D1 
D8 +2d 
D9 +2d 
D15 +2d 
D22+14d 
D43+ 7d 
D84 ± 14d 
D174 ± 14d  
D374 ± 14d  
 
 
Study Day post Vaccination #3  
 
 
 
 
 
Dose  3 D1 
D2 +2d 
D8 +2d 
D15+14d 
D36+ 7d 
D77 ± 14d 
D167 ± 14d  
D367 ± 14d  
 
 
Study Day post Vaccination #4  
 
 
 
 
 
 
 
Dose 4   
D1 
D8+14d 
D29+ 7d 
D70 ± 14d 
D160 ± 14d  
D360 ± 14d  
 
 
Blood for developer 
assaysh   X X X X X X X       
aConccom itant medications associated with new onset chronic medical condition(s)  
bHeight and weight will also be measured at the 1st and 2nd screening visits to calculate BMI  
cOnly SAEs  
dVaccination site will be examined for local reactions if early termination vi sit occurs ≤28 days after last injection; memory aid will be reviewed if early termination visit occurs 
≤15 days after last injection  
eVaccination site will be examined for local reactions if unscheduled visit occurs ≤28 days after any vaccination , and if so, determine whether information recorded by subject on 
the memory aid conforms to examination  
fClinical labs drawn at 1st screening visit will also include HIV -1/2 antibody, HBsAg, and HCV antibody  
gAssay  will be done only for those with positive IFNγ  reponse by T cell ELISpot assay  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial  19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           106 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017  hDetailed in Appendix  B 
Abbreviations:  X = study procedure for all Groups, (X) = optional procedures to be determined by study staff, RFFIT = rapid 
fluorescent focus inhibition test   
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial  19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           107 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017  APPENDIX  B. TABLE OF BLOOD VOLUME COLLECTION (ML)  
Study Visit  1st 
Screen 
(D-42 to 
-1) 2nd 
Screen (D 
-42 to -1) V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 Early 
termination  Unscheduled  
Study Day post Vaccination #1 (D1)  
 
 
D1 
D2 
D8 
D15 
D16 
D22 
D29 
D50 
D91 
D181  
D381  
 
 
Blood draw  X  X X X X X X X  X X X X (X) 
Clinical Laboratory  Chemistry  
(SST 8mL)  8   8 8  8 8   
   X  
Hematology  
(EDTA 4mL)  4   4 4  4 4   
   X  
Screening serology  
(SST 8mL)  8          
     
Serum Preg  
(SST 3.5mL)  3.5          
     
Urine dipstick  X               
Immunolog y 
(all samples on 
vaccination days will 
be collected before the 
vaccine dose is given)  Rabies nAb (RFFIT)  
(SST, 8mL)    16  16 16  16 16  
16 16 16 X  
Anti-vector Ab  
(SST, 4mL)    4      4  
     
T cell (IFNγ ELISpot)  
(8mL CPT tubes)    8   8   8  
8  8   
T cell (ICS)  
 (8mL CPT tubes)       16*   16*  
     
MBC ELISpot  
(8mL CPT tubes)    8        
8 8 8   
PBMCs for future use    16   16   16  16 16 16   
Blood for PAXgene (early 
vaccine response)  (future use)    5 5 5 5 5 5 5       
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial  19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           108 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017  Study Visit  1st 
Screen 
(D-42 to 
-1) 2nd 
Screen (D 
-42 to -1) V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 Early 
termination  Unscheduled  
Study Day post Vaccination #1 (D1)  
 
 
D1 
D2 
D8 
D15 
D16 
D22 
D29 
D50 
D91 
D181  
D381  
 
 
Blood fo r multiplex protein 
assay (early vaccine response)  
(future use)  
(SST, 8mL)    8 8 8 8 8 8 8  
     
Blood volume per visit  23.5  65 25 41 69 25 41 73  48 40 48   
Total blood volume 
(cumulative)  23.5  88.5 113.5  154.5  223.5  248.5  289.5  362.5   410.5  450.5  498.5    
*Assay will be done only for those with positive IFNγ  reponse by T cell ELISpot assay  
 
  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial  19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           109 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017  APPENDIX  C. TOXICITY TABLE  
 
Local (Injection Site) Reactogenicity Grading  
Local (Injection Site) 
Reaction  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Pain – experienced 
without touching the 
injection site 
(spontaneous discomfort)  Subject is aware of pain, 
but it does not interfere 
with daily activity,  and it 
does not require  pain 
medication or it requires 
use of a non -narcotic pain 
reliever ≤24hours  Subject is aware of pain; 
there is interference with 
daily activity  or it 
requires repeated use of a 
non-narcotic pain reliever 
for >24 hours  Subject is aware of pain, 
and it prevents daily 
activity or requires any use 
of a narcotic pain reliever  
Tenderness – hurts only 
when injection site is 
touched or the arm is 
moved  The area immediately 
surrounding the injection 
site hurts only when 
touched or with arm 
motion, and it does not 
interfere with daily 
activity  The area immediately 
surrounding the in jection 
site hurts when touched or 
with arm motion, and it 
interferes with daily 
activity  The area immediately 
surrounding the injection 
site hurts when touched or 
with arm motion, and it 
prevents daily activity  
Pruritus (Itching)  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial  19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           110 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017  Local (Injection Site) 
Reaction  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Ecchymosis (Bruising)*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Erythema (Redness)*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Induration 
(Hardness)/Swelling*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
* Size w ill also be measured in mm but will not be used as a halting criteri on. 
 
Ecchymosis (bruising), erythema (redness), and induration (hardness)/swelling as analyzed by measurement will be graded as fo llows:  
Local (Injection Site) Reactogenicity Measurements  
Local (Injection Site) Reaction  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Ecchymosis (Bruising)*  25 mm – 50 mm 51 mm – 100 mm >100 mm 
Erythema (Redness)*  25 mm – 50 mm 51 mm – 100 mm >100 mm 
Induration (Hardness)/Swelling*  25 mm – 50 mm 51 mm – 100 mm >100 mm 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial  19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           111 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017  * Will not be used as halting criteria.  
Subjective Systemic Reactogenicity Grading  
Systemic (Subjective)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Feverishness 
(Chills/Shivering/Sweating)  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Fatigue (Tiredness)  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Malaise (General Unwell 
Feeling)  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Myalgia (Body 
Aches/Muscular Pain)*  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Arthralgia (Joint Pain)*  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Headache  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Nausea  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
* Not at injection site.  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial  19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           112 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017   
 
Oral temperature# will be graded as follows:  
Quantitative Systemic Reactogenicity Grading  
Systemic (Quantitative)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Fever* - oral† 38.0°C – 38.4°C  
100.4°F – 101.1°F  38.5°C – 38.9°C  
101.2°F – 102.0°F  >38.9°C  
>102.0°F  
# Oral temperature assessed on Day 1 prior to the first study vaccination will be considered as baseline.  
* A fever can be considered not related to the vaccine  if an alternative etiology can be documented.  
† Subjects mu st not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature.  
Additional Adverse Event Severity Grading  
Pulse and blood pressure# will be graded as follows:  
Physiologic Parameter  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Bradycardia - beats per minute  50 – 54 45 – 49 <45 
Tachycardia - beats per minute  101 – 115 116 – 130 >130 
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial  19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           113 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017  Hypotension (systolic) mmHg  85 – 89 80 – 84 <80 
Hypotension (diastolic) mmHg  50 – 54 45 – 49 <45 
Hypertension (systolic) mmHg  141 – 150 151 – 155 >155 
Hypertension (diastolic) mmHg  91 – 95 96 – 100 >100 
# Pulse and blood pressure assessed on Day 1 prior to the first study vaccination will be considered as baseline.  
  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial  19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           114 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017  Clinical safety laboratory results * will be graded as follows:  
Clinical Safety Laboratory Adverse Event * 
Hematology  Normal Range  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
WBC 103/µL (Decrease)  3.8 – 10.8 2.5 – 3.7 1.5 – 2.4 <1.5 
WBC 103/µL (Increase)  3.8 – 10.8 10.9 – 15.0 15.1 – 20.0 >20.0  
Hgb g/dL (Decrease) (Female)  11.7 – 15.5 11.0 – 11.6 9.5 – 10.9 <9.5 
Hgb g/dL (Decrease) (Male)  13.2 – 17.1 12.0 – 13.1 10.0 – 11.9 <10.0 
Platelets 103/µL (Decrease)  140 – 400 125 – 139 100 – 124 <100  
Platelets 103/µL (Increase)  140 – 400 401 – 550 551– 750 >750  
Absolute Lymphocyte Count 103/µL 0.85 – 3.9 0.65 – 0.84 0.5 – 0.64 <0.5 
Absolute Neutrophil Count 103/µL 1.5 – 7.8  1.2 – 1.49 1.0 – 1.19 <1.0 
     
Chemistry  Normal Range  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
AST IU/L (increase) (Male)  10 – 40 1.1 – 2.5 x ULN  > 2.5 – 5.0 x ULN  > 5.0 – 10 x ULN  
AST IU/L (increase) (Female)  10 – 30 1.1 – 2.5 x ULN  > 2.5 – 5.0 x ULN  > 5.0 – 10 x ULN  
ALT IU/L (increase) (Male)  9 – 46 1.1 – 2.5 x ULN  > 2.5 – 5.0 x ULN  > 5.0 – 10 x ULN  
ALT IU/L (increase) (Female)  6 – 29 1.1 – 2.5 x ULN  > 2.5 – 5.0 x ULN  > 5.0 – 10 x ULN  
DMID Protocol 17 -0089  Version 7.0 Rabies Vaccine Phase 1 Trial  19 Jan 2023 
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH           115 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 2.0, Dated August 10, 2017  Total Bilirubin mg/dL (Increase) – 
when accompanied by any increase 
in ALT  0.2 – 1.2 1.1 – 1.25 x ULN  > 1.25 – 1.5 x ULN  > 1.5 – 1.75 x ULN  
Total Bilirubin mg/dL (Increase) – 
when ALT is normal  0.2 – 1.2 1.1 – 1.5 x ULN  > 1.5 – 2.0 x ULN  > 2.0 – 3.0 x ULN  
Blood urea nitrogen (BUN) mg/dL 
(increase)  7 – 25 26 – 29 30 – 34 >34 
Creatinine mg/dL (Increase) (Male)  0.60 – 1.35 1.36 – 1.70 1.71 – 2.00 >2.00  
Creatinine mg/dL (Increase) 
(Female)  0.50 – 1.10 1.11 – 1.70 1.71 – 2.00 >2.00  
 
*Clinical laboratory evaluations assessed at the screening visit will be considered as baseline 
 